詳細検索

詳細検索

お問い合わせ

製品、技術、サービス種別、用途別の空間ゲノミクスおよびトランスクリプトミクス市場 ― 2031年までの世界予測

製品、技術、サービス種別、用途別の空間ゲノミクスおよびトランスクリプトミクス市場 ― 2031年までの世界予測


Spatial Genomics & Transcriptomics Market by Product, Technique, Service Type, Application - Global Forecast to 2031

空間ゲノミクスおよびトランスクリプトミクス市場は、予測期間中に年平均成長率(CAGR)12.9%で拡大し、2026年の0.67億米ドルから2031年には1.23億米ドルに達すると見込まれています。 この市場は、腫瘍学研究... もっと見る

 

 

出版社
MarketsandMarkets
マーケッツアンドマーケッツ
出版年月
2026年11月9日
電子版価格
US$4,950
シングルユーザーライセンス
ライセンス・価格情報/注文方法はこちら
納期
通常2営業日以内
ページ数
451
図表数
657
言語
英語

英語原文をAIを使って翻訳しています。


 

サマリー

空間ゲノミクスおよびトランスクリプトミクス市場は、予測期間中に年平均成長率(CAGR)12.9%で拡大し、2026年の0.67億米ドルから2031年には1.23億米ドルに達すると見込まれています。 この市場は、腫瘍学研究、精密医療、創薬、バイオマーカーの同定、およびトランスレーショナル研究における空間プロファイリングの利用拡大に牽引され、着実に成長すると見込まれています。 空間トランスクリプトミクス、イン・シトゥハイブリダイゼーション、シーケンシングに基づく空間解析、ハイプレックス分子イメージングなどの技術により、遺伝子発現、細胞間相互作用、組織構造、および疾患メカニズムの解明が可能となります。これらのツールは、がん研究、治療標的の同定、治療反応の評価、神経科学、免疫学、発生生物学にわたる応用を支えています。 単一細胞解析、マルチオミクス統合、およびAIを活用した空間データの解釈に対する関心の高まりは、製薬、バイオテクノロジー、学術、臨床研究、CROの各分野における導入をさらに後押ししています。 さらに、高解像度の機器、信頼性の高いアッセイキット、バリデーション済みのプローブ、シーケンシング試薬、自動試料前処理、およびバイオインフォマティクス・ソリューションへの需要が高まることで、ワークフローの効率化とデータ品質の向上が図られています。

2026年から2031年にかけて、空間ゲノミクス・トランスクリプトミクス製品市場において、空間ゲノミクス分野が最も高い年平均成長率(CAGR)で成長すると見込まれる
技術別では、無傷の組織内における遺伝子発現の高解像度解析に対する需要の高まりを背景に、空間ゲノミクス分野が予測期間中に最も高いCAGRで成長すると見込まれています。 腫瘍学、バイオマーカー発見、創薬、精密医療における応用分野の拡大に伴い、空間プロファイリングと高度なデータ解析を統合した専門サービスの需要が高まっています。これらのサービスは、研究者が細胞間の相互作用、組織構造、疾患に関連する分子パターンを解明するのを支援し、製薬、バイオテクノロジー、学術研究の各分野において、より深い生物学的知見の獲得を支えています。

2025年には、シーケンシング・分析サービス部門が、空間ゲノミクスおよびトランスクリプトミクスサービス市場において最大のシェアを占める見通しである
種類別に見ると、2025年には、複雑な空間的分子データの処理および解釈に対するニーズの高まりを背景に、シーケンシング・分析サービス部門がサービス市場で最大のシェアを占める見通しです。これらのサービスにより、研究者は遺伝子発現パターンの分析、細胞間の相互作用の特定、および組織の不均一性の解明が可能になります。 腫瘍学、バイオマーカー発見、創薬、トランスレーショナルリサーチにおける応用分野の拡大により、製薬企業、バイオテクノロジー企業、および学術研究機関全体での需要が引き続き支えられています。

2026年から2031年にかけて、空間ゲノミクスおよびトランスクリプトミクス市場において、北米は2番目に高い年平均成長率(CAGR)を記録する見込みである
地域別に見ると、北米では、精密医療への多額の投資、先進的な生物医学研究インフラ、および空間プロファイリング技術の採用拡大に支えられ、予測期間中に力強い市場成長が見込まれています。 10x Genomics(米国)、Illumina, Inc.(米国)、Bruker(米国)をはじめとする主要企業は、製品の革新やプラットフォームの開発を通じて、同地域の成長を支えている。 腫瘍学、神経科学、バイオマーカー発見、創薬分野での応用拡大に加え、製薬業界の研究開発投資や共同研究が相まって、同地域全体での技術導入が加速すると予想される。

本レポートのために実施された一次インタビューは、次のように分類できます。
- 回答者別:供給側 – 70%、需要側 – 30%
- 役職別:マネージャー – 45%、CXOおよびディレクター – 30%、エグゼクティブ – 25%
- 地域別:北米 – 40%、欧州 – 25%、アジア太平洋 – 25%、ラテンアメリカ – 5%、中東・アフリカ – 5%

10x Genomics(米国)、Bio-Techne(米国)、Bruker(米国)、Standard BioTools Inc.(米国)、Illumina, Inc.(米国)、 Bio-Rad Laboratories, Inc.(米国)、Visiopharm A/S(デンマーク)、Danaher Corporation(米国)、Velsera Inc.(米国)、およびRevvity, Inc.(米国)は、空間ゲノミクスおよびトランスクリプトミクス関連の製品やサービスを提供する主要企業の一部である。

調査対象分野
本調査レポートでは、空間ゲノミクスおよびトランスクリプトミクス市場を「提供内容(製品およびサービス)」別に、製品市場を「技術(空間トランスクリプトミクスおよび空間ゲノミクス)」別に、 サービス市場をタイプ別(サンプル前処理サービス、シーケンシング・分析サービス、データ可視化・分析サービス)および用途別(トランスレーショナルリサーチ、創薬・医薬品開発)に分類し、製品市場をエンドユーザー別(製薬・バイオテクノロジー企業、学術・研究機関、 CROおよびCDMO、臨床診断検査機関)による製品市場、エンドユーザー別(製薬・バイオ医薬品企業、学術・研究機関、その他のエンドユーザー)によるサービス市場、および地域別(北米、欧州、アジア太平洋、ラテンアメリカ、中東、アフリカ)に分類している。

本レポートの範囲には、空間ゲノミクスおよびトランスクリプトミクス市場の成長に影響を与える主要な要因(推進要因、制約要因、課題、機会など)に関する詳細な情報が含まれています。 主要な業界プレイヤーについて包括的な分析を行い、各社の事業概要、製品・サービスポートフォリオ、主要戦略、新製品・サービスの立ち上げ、買収、および市場に関連する最近の動向に関する洞察を提供しています。また、本レポートには、空間ゲノミクスおよびトランスクリプトミクスのエコシステムにおいて台頭しつつあるスタートアップ企業に関する競合分析も含まれています。

本レポートを購入する主なメリット
本レポートは、市場全体およびそのサブセグメントの収益予測を提供することで、市場をリードする企業や新規参入企業を支援します。また、ステークホルダーが競争環境をより深く理解し、自社のビジネスを効果的に位置づけ、適切な市場参入戦略を策定するための知見を得る上でも役立ちます。 本レポートは、ステークホルダーが市場の動向を把握できるようにするとともに、主要な市場推進要因、制約要因、機会、課題に関する情報を提供します。

本レポートでは、以下のポイントについて洞察を提供しています:
- 市場の動向:主要な推進要因(創薬・開発における空間ゲノミクスおよびトランスクリプトミクスの採用拡大、新規の空間ゲノミクスおよびトランスクリプトミクス製品の導入、製薬分野の研究開発投資および官民資金の増加)、制約要因 (初期設備投資および維持コストの高さ、データの複雑さと計算リソースの要件の高さ)、機会(バイオマーカー同定における空間オミクスの利用拡大、精密医療および標的指向型医薬品開発への需要の高まり)、および課題(空間技術全般にわたる標準化と再現性の欠如)が、空間ゲノミクスおよびトランスクリプトミクス市場の成長に与える影響
- 製品開発/イノベーション:市場に新たに投入された製品やイノベーションに関する詳細な洞察
- 市場開発:収益性の高い市場に関する包括的な情報および各地域にわたる市場分析
- 市場の多角化:新製品、未開拓地域、最近の動向、および市場への投資に関する網羅的な情報
- 競合評価:10x Genomics(米国)、Bio-Techne(米国)、Bruker(米国)、Standard BioTools Inc.(米国)、Illumina, Inc.(米国)、 Bio-Rad Laboratories, Inc.(米国)、Visiopharm A/S(デンマーク)、Danaher Corporation(米国)など、市場における主要企業の市場シェア、成長戦略、製品・サービスに関する詳細な評価



お問い合わせ

お問合せ種類/内容 *

補足が有ればご記入ください
貴社名*
ご担当者名 * 姓 名
メールアドレス *

ページTOPに戻る


目次

1 はじめに 41
1.1 本調査の目的 41
1.2 市場の定義 41
1.3 本調査の範囲 42
1.3.1 市場のセグメンテーション 42
1.3.2 対象地域 43
1.3.3 調査対象の範囲および除外項目 43
1.3.4 調査対象期間 44
1.3.5 調査対象通貨 44
1.4 ステークホルダー 44
1.5 変更点の概要 45

2 概要 46
2.1 市場のハイライトと主要な洞察 46
2.2 主要市場参加者:戦略的展開の分析 48
2.3 空間ゲノミクスおよびトランスクリプトミクス市場における破壊的トレンド 49
2.4 高成長セグメント 50
2.5 地域別概況:市場規模、成長率、および予測 51

3 プレミアム・インサイト 52
3.1 空間ゲノミクスおよびトランスクリプトミクス市場の概要 52
3.2 北米:空間ゲノミクスおよびトランスクリプトミクス市場(提供サービス別) 53
3.3 空間ゲノミクスおよびトランスクリプトミクス市場:地域別の成長機会 54
3.4 空間ゲノミクスおよびトランスクリプトミクス市場のシェア(用途別)、

2026年 対 2031年 (%) 54

4 市場の概要 55
4.1 はじめに 55
4.2 市場の動向 55
4.2.1 成長要因 56
4.2.1.1 創薬および医薬品開発における空間ゲノミクスおよびトランスクリプトミクスの採用拡大 56
4.2.1.2 新規の空間ゲノミクスおよびトランスクリプトミクス製品の導入 57
4.2.1.3 製薬分野における研究開発投資および官民資金の増加 58
4.2.2 制約要因 59
4.2.2.1 初期設備投資および維持コストの高さ 59
4.2.2.2 データの複雑さと計算要件の高さ 59
4.2.3 機会 60
4.2.3.1 バイオマーカー同定における空間オミクスの利用拡大 60
4.2.3.2 精密医療および標的指向型医薬品開発への需要の高まり 61
4.2.4 課題 61
4.2.4.1 空間技術間の標準化および再現性の欠如 61
4.3 未充足ニーズと未開拓領域 62
4.4 相互に関連する市場とセクター横断的な機会 63
4.5 ティア1/2/3のプレーヤーによる戦略的動き 63

5 業界の動向 65
5.1 ポーターの5つの力分析 65
5.1.1 競争の激しさ 66
5.1.2 供給者の交渉力 66
5.1.3 購入者の交渉力 67
5.1.4 代替品からの脅威 67
5.1.5 新規参入者からの脅威 67
5.2 マクロ経済の見通し 68
5.2.1 はじめに 68
5.2.2 GDPの推移と予測 68
5.2.3 世界のヘルスケア産業の動向 68
5.2.4 世界のバイオテクノロジー産業の動向 69
5.3 バリューチェーン分析 69
5.4 エコシステム分析 71
5.4.1 エコシステムにおける各プレーヤーの役割 72
5.5 価格分析 73
5.5.1 主要プレーヤー別平均販売価格の推移(2023年~2025年) 73
5.5.1.1 医療機器 73
5.5.1.2 消耗品 74
5.5.2 地域別平均販売価格の推移(2023年~2025年) 75
5.6 貿易分析 76
5.6.1 輸入シナリオ(HSコード9027) 76
5.6.2 輸出シナリオ(HSコード9027) 77
5.7 主要な会議・イベント(2026年~2027年) 78
5.8 顧客のビジネスに影響を与えるトレンド/ディスラプション 78
5.9 投資および資金調達のシナリオ 79
5.10 ケーススタディ分析 80
5.10.1 高解像度空間トランスクリプトミクスによる
80
5.10.2 COSMXによる全トランスクリプトームイメージングが明らかにした腎がんにおける分子的不均一性 80
5.10.3 統合空間ゲノミクスおよびトランスクリプトミクスによる乳がんのゲノム組織化の解明 81
5.11 2025年の米国関税が及ぼす影響—空間ゲノミクスおよびトランスクリプトミクス市場 81
5.11.1 はじめに 81
5.11.2 主な関税率 82
5.11.3 価格への影響分析 83
5.11.4 国・地域への影響 84
5.11.4.1 米国 84
5.11.4.2 欧州 84
5.11.4.3 アジア太平洋地域 85
5.11.5 最終用途産業への影響 85
5.11.5.1 製薬・バイオテクノロジー企業 85
5.11.5.2 学術・研究機関 86
5.11.5.3 CROおよびCDMO 86
5.11.5.4 臨床診断検査機関 86

6 技術の進歩、AIがもたらす影響、特許、イノベーション、および将来の応用 87
6.1 技術分析 87
6.1.1 主要技術 87
6.1.1.1 イン・シトゥ・シーケンシング 87
6.1.1.2 イン・シトゥ・ハイブリダイゼーション 87
6.1.1.3 空間バーコーディングおよびシーケンシング 87
6.1.2 補完的技術 88
6.1.2.1 組織イメージングおよび組織病理学的解析 88
6.1.2.2 空間ヒートマップ 88
6.1.2.3 遺伝子発現差の解析 88
6.1.3 関連技術 89
6.1.3.1 マルチオミクス 89
6.1.3.2 メタボロミクス 89
6.1.3.3 単一細胞解析 89
6.2 技術ロードマップ 89
6.3 特許分析 90
6.3.1 方法論 90
6.3.2 出願特許数(文書種別別) 90
6.3.3 主要特許一覧 92
6.4 将来の応用 92
6.5 AI/生成AIが空間ゲノミクスおよびトランスクリプトミクス市場に与える影響 93
6.5.1 主なユースケースと市場の可能性 94
6.5.2 AIを活用した空間ゲノミクスおよびトランスクリプトミクス・ワークフローにおけるベストプラクティス 95
6.5.3 空間ゲノミクスおよびトランスクリプトミクス市場におけるAI導入の事例研究 95
6.5.4 相互に関連する隣接エコシステムと市場プレイヤーへの影響 96
6.5.5 AI統合型空間ゲノミクスおよびトランスクリプトミクス技術の導入に対する顧客の準備状況 96

7 規制環境と持続可能性への取り組み 98
7.1 地域ごとの規制とコンプライアンス 98
7.1.1 規制機関、政府機関およびその他の組織 98
7.1.2 業界基準 100
7.2 サステナビリティの取り組み 101
7.3 規制政策がサステナビリティの取り組みに与える影響 102
7.4 認証、表示、および環境基準 102

8 顧客環境と購買行動 105
8.1 意思決定プロセス 105
8.2 購入者のステークホルダーおよび購入評価基準 105
8.2.1 購入プロセスにおける主要なステークホルダー 105
8.2.2 エンドユーザー別(製品)の主要な購入基準 106
8.2.3 エンドユーザー別(サービス)の主要な購入基準 107
8.3 導入の障壁と内部的な課題 108
8.4 さまざまな最終用途産業における未充足ニーズ 109

9 空間ゲノミクスおよびトランスクリプトミクス市場(提供サービス別) 110
9.1 はじめに 111
9.2 製品 111
9.2.1 機器およびソフトウェア 114
9.2.1.1 詳細な空間マッピングおよびマルチオミクス解析を可能にし、疾患研究を促進する機器およびソフトウェア 114
9.2.2 消耗品 117
9.2.2.1 腫瘍学および精密医療における空間ゲノミクス研究を推進するための、再現性が高く質の高いデータ収集 117
9.3 サービス 120
9.3.1 市場成長を促進するための、精密医療における高品質な空間データへの需要の高まり 120

10 空間ゲノミクスおよびトランスクリプトミクス製品市場、
技術別 124
10.1 はじめに 125
10.2 空間トランスクリプトミクス 125
10.2.1 免疫組織化学 128
10.2.1.1 バイオマーカー発見や組織構造内での細胞間相互作用における応用拡大が、この分野を牽引している 128
10.2.2 RNAシーケンシング 131
10.2.2.1 イン・シトゥRNAシーケンシング 134
10.2.2.1.1 複雑なデータセットの解釈を容易にするため、ISSとデータ解析用バイオインフォマティクス・ツールキットの統合 134
10.2.2.2 単一細胞RNAシーケンシング 136
10.2.2.2.1 市場におけるscRNA-seqプラットフォームの普及拡大とバイオインフォマティクスツールの進歩が、当該セグメントを牽引 136
10.2.2.3 その他のRNAシーケンシング 139
10.2.3 イン・シトゥハイブリダイゼーション 141
10.2.3.1 がん研究および発生生物学におけるハイスループットかつ3D空間的遺伝子発現解析が市場を牽引 141
10.2.4 顕微鏡を用いたRNAイメージング 144
10.2.4.1 組織構造内における分子間コミュニケーションの理解を深め、セグメントの成長を促進 144
10.2.5 免疫蛍光法 147
10.2.5.1 がんの診断および予後評価に向けた免疫・腫瘍微小環境の高度なプロファイリングによるセグメント成長の促進 147
10.2.6 レーザーキャプチャーマイクロダイセクション 150
10.2.6.1 特定の細胞集団からの遺伝子発現データの解析による、組織切片内での空間マッピングの促進 150
10.2.7 その他の空間トランスクリプトミクス技術 153
10.3 空間ゲノミクス 155
10.3.1 イン・シトゥ・ハイブリダイゼーション 158
10.3.1.1 市場成長を牽引する高特異性検出プラットフォームへの需要 158
10.3.2 レーザーキャプチャーマイクロダイセクション 161
10.3.2.1 不均一な組織サンプル内の細胞メカニズムおよび分子プロファイルに関する詳細な知見がセグメントを牽引 161
10.3.3 ゲノムシーケンシング 164
10.3.3.1 マイクロディセクションに基づくシーケンシング 167
10.3.3.1.1 セグメントの成長を後押しする精密医療への需要の高まり 167
10.3.3.2 クロマチンアクセシビリティシーケンシング 170
10.3.3.2.1 セグメントの成長を後押しするための、遺伝子発現制御およびエピジェネティック修飾に関する知見の必要性 170
10.3.3.3 その他のゲノムシーケンシング 172
10.3.4 その他の空間ゲノミクス技術 175

11 空間ゲノミクスおよびトランスクリプトミクス・サービス市場(種類別) 178
11.1 はじめに 179
11.2 試料調製サービス 179
11.2.1 市場成長を促進するための、組織サンプル内における遺伝子発現の正確な空間解析の必要性 179
11.3 シーケンシングおよび解析サービス 182
11.3.1 シーケンシングおよびバイオインフォマティクス解析のための先進技術を活用したシーケンシングおよび解析サービス 182
11.4 データ可視化・解析サービス 184
11.4.1 市場の成長を支える、複雑な空間ゲノミクスデータの解釈に向けた高度なツールへの需要の高まり 184

12 空間ゲノミクスおよびトランスクリプトミクス市場(用途別) 188
12.1 はじめに 189
12.2 トランスレーショナルリサーチ 189
12.2.1 がん 192
12.2.1.1 がん研究における腫瘍組織内のDNAおよびRNAの正確な位置を特定するための空間ゲノミクスおよびトランスクリプトミクス 192
12.2.2 免疫学 195
12.2.2.1 市場成長を促進するための、免疫細胞間の相互作用および組織特異的な免疫応答の理解深化の必要性 195
12.2.3 神経科学 197
12.2.3.1 市場の成長を促進するため、脳の機能および機能障害を分析する細胞の多様性のマッピングへの注目が高まっている 197
12.2.4 感染症 200
12.2.4.1 導入を促進するためには、組織レベルでの病原体と宿主の相互作用に関する理解を深める必要がある 200
12.2.5 その他の疾患 203
12.3 創薬・開発 206
12.3.1 疾患管理および創薬におけるRNA-SEQの利用拡大が市場を牽引 206

13 空間ゲノミクス・トランスクリプトミクス製品市場
エンドユーザー別 209
13.1 はじめに 210
13.2 学術・研究機関 210
13.2.1 市場の成長を後押しする、複雑な生物系に関する基礎的な発見と細胞レベルの知見への注力 210
13.3 CROS および CDMOS 213
13.3.1 市場成長を牽引する、分子の空間的分布に関する精密な知見への需要の高まり 213
13.4 製薬・バイオテクノロジー企業 216
13.4.1 製薬・バイオテクノロジー企業による疾患研究の変革と薬剤ターゲット検証の効率化 216
13.5 臨床診断検査機関 219
13.5.1 病原体検出およびゲノム解析における診断精度の向上による市場成長の促進 219

14 空間ゲノミクスおよびトランスクリプトミクス・サービス市場(エンドユーザー別) 223
14.1 はじめに 224
14.2 学術・研究機関 224
14.2.1 市場成長を促進するための細胞環境のマッピングおよび疾患メカニズムの研究に必要なツール 224
14.3 製薬・バイオテクノロジー企業 227
14.3.1 バイオマーカー開発の最適化と臨床試験デザインの改善を目指す製薬・バイオテクノロジー企業 227
14.4 その他のエンドユーザー 230

15 地域別空間ゲノミクス・トランスクリプトミクス市場 234
15.1 はじめに 235
15.2 北米 236
15.2.1 米国 241
15.2.1.1 予測期間中、北米の空間ゲノミクスおよびトランスクリプトミクス市場は米国が主導する見込み 241
15.2.2 カナダ 246
15.2.2.1 政府による好意的な施策と感染症の高い発生率が市場成長を後押し 246
15.3 ヨーロッパ 251
15.3.1 ドイツ 256
15.3.1.1 先進的なゲノミクス研究と主要企業の存在が市場成長を促進 256
15.3.2 英国 261
15.3.2.1 政府資金の増加と新たな診断用バイオマーカーへの需要の高まりが市場成長を後押し 261
15.3.3 フランス 265
15.3.3.1 ライフサイエンス分野の研究開発への投資拡大とバイオテクノロジー企業の増加が市場成長を牽引 265
15.3.4 イタリア 270
15.3.4.1 疾患研究への注力の強化と診断能力の拡大が市場成長を後押し 270
15.3.5 スペイン 274
15.3.5.1 先進的ながん研究への注力と、個別化医療へのニーズの高まりが市場成長を牽引 274
15.3.6 その他の欧州諸国 279
15.4 アジア太平洋地域 284
15.4.1 中国 290
15.4.1.1 国内の空間技術の進歩とAIを活用したデータ分析が、空間生物学の研究を強化している 290
15.4.2 日本 294
15.4.2.1 戦略的な買収と統合された空間ワークフローが技術導入を加速させている 294
15.4.3 インド 299
15.4.3.1 ゲノミクス研究の拡大と精密腫瘍学が、空間解析技術に新たな機会を創出している 299
15.4.4 韓国 303
15.4.4.1 バイオテクノロジーへの投資と研究アクセスプログラムが、空間トランスクリプトミクスの導入を後押ししている 303
15.4.5 オーストラリア 308
15.4.5.1 研究インフラと産業界との連携が、空間オミクス技術へのアクセスを拡大している 308
15.4.6 アジア太平洋地域のその他 312
15.5 ラテンアメリカ 317
15.5.1 ブラジル 322
15.5.1.1 国家ゲノムイニシアチブと精密公衆衛生が、空間トランスクリプトミクスの導入に向けた道筋を築いている 322
15.5.2 メキシコ 327
15.5.2.1 ゲノム研究インフラと計算科学の専門知識の強化が、空間生物学の機会を支えている 327
15.5.3 その他のラテンアメリカ諸国 331
15.6 中東 336
15.7 アフリカ 341

16 競争環境 346
16.1 はじめに 346
16.2 主要企業の戦略/「勝利への権利」、2023年1月~2026年9月 346
16.2.1 主要企業の戦略の概要、
2023年1月~2026年9月 346
16.3 売上高分析、2021年~2025年 348
16.4 市場シェア分析、2025年 349
16.5 企業評価マトリックス:主要企業、2025年 352
16.5.1 スター企業 352
16.5.2 新興リーダー企業 352
16.5.3 広範な展開を行う企業 352
16.5.4 参入企業 352
16.5.5 企業の事業展開:主要企業、2025年 354
16.5.5.1 企業の事業展開 354
16.5.5.2 地域別事業展開 354
16.5.5.3 提供サービス別事業展開 355
16.5.5.4 技術別事業展開 356
16.5.5.5 アプリケーションの展開状況 356
16.6 企業評価マトリックス:スタートアップ/中小企業、2025年 357
16.6.1 先進的な企業 357
16.6.2 対応力のある企業 357
16.6.3 ダイナミックな企業 357
16.6.4 スタートブロック 357
16.6.5 競争力ベンチマーク: スタートアップ/中小企業、2025年 359
16.6.5.1 主要なスタートアップ/中小企業の詳細リスト 359
16.6.5.2 スタートアップ/中小企業の競合ベンチマーキング 360
16.7 企業評価と財務指標 361
16.7.1 企業評価 361
16.7.2 企業評価 361
16.8 ブランド比較 362
16.9 競合状況 363
16.9.1 新製品発売 363
16.9.2 取引 364
16.9.3 事業拡大 365

17 企業概要 366
17.1 主要企業 366
17.1.1 10X GENOMICS 366
17.1.1.1 事業概要 366
17.1.1.2 提供製品・サービス・ソリューション 367
17.1.1.3 最近の動向 369
17.1.1.3.1 製品・サービスの発売 369
17.1.1.3.2 取引 370
17.1.1.3.3 事業拡大 371
17.1.1.4 MnMの見解 372
17.1.1.4.1 主な強み 372
17.1.1.4.2 戦略的選択 372
17.1.1.4.3 弱点および競合上の脅威 372
17.1.2 BIO-TECHNE 373
17.1.2.1 事業概要 373
17.1.2.2 提供製品・サービス・ソリューション 374
17.1.2.3 最近の動向 376
17.1.2.3.1 製品・サービスの発売 376
17.1.2.3.2 取引 377
17.1.2.4 MnMの見解 377
17.1.2.4.1 主な強み 377
17.1.2.4.2 戦略的選択 377
17.1.2.4.3 弱点および競合上の脅威 378
17.1.3 BRUKER 379
17.1.3.1 事業概要 379
17.1.3.2 提供製品・サービス・ソリューション 380
17.1.3.3 最近の動向 381
17.1.3.3.1 取引 381
17.1.3.4 MnMの見解 382
17.1.3.4.1 主な強み 382
17.1.3.4.2 戦略的選択 382
17.1.3.4.3 弱点および競合上の脅威 383
17.1.4 スタンダード・バイオツールズ社 384
17.1.4.1 事業概要 384
17.1.4.2 提供製品・サービス・ソリューション 385
17.1.4.3 最近の動向 387
17.1.4.3.1 新製品の発売 387
17.1.4.3.2 取引 388
17.1.4.4 MnMの見解 388
17.1.4.4.1 主な強み 388
17.1.4.4.2 戦略的選択 388
17.1.4.4.3 弱点および競合上の脅威 388
17.1.5 ILLUMINA, INC. 389
17.1.5.1 事業概要 389
17.1.5.2 提供製品・サービス・ソリューション 390
17.1.5.3 最近の動向 391
17.1.5.3.1 製品発売 391
17.1.5.3.2 取引 392
17.1.5.4 MnMの見解 392
17.1.5.4.1 主な強み 392
17.1.5.4.2 戦略的選択 392
17.1.5.4.3 弱点および競合上の脅威 392
17.1.6 BIO-RAD LABORATORIES, INC. 393
17.1.6.1 事業概要 393
17.1.6.2 提供製品・サービス・ソリューション 394
17.1.6.3 最近の動向 395
17.1.6.3.1 新製品の発売 395
17.1.6.3.2 取引 395
17.1.6.4 MnMの見解 395
17.1.6.4.1 主な強み 395
17.1.6.4.2 戦略的選択 395
17.1.6.4.3 弱点および競合上の脅威 396
17.1.7 VISIOPHARM A/S 397
17.1.7.1 事業概要 397
17.1.7.2 提供製品・サービス・ソリューション 397
17.1.7.3 最近の動向 398
17.1.7.3.1 新製品の発売 398
17.1.8 ダナハー・コーポレーション 399
17.1.8.1 事業概要 399
17.1.8.2 提供製品・サービス・ソリューション 400
17.1.8.3 最近の動向 401
17.1.8.3.1 取引 401
17.1.9 VELSERA INC. 402
17.1.9.1 事業概要 402
17.1.9.2 提供している製品・サービス・ソリューション 402
17.1.10 REVVITY, INC. 403
17.1.10.1 事業概要 403
17.1.10.2 提供している製品・サービス・ソリューション 404
17.1.10.3 最近の動向 405
17.1.10.3.1 取引実績 405
17.1.11 VIZGEN, INC. 406
17.1.11.1 事業概要 406
17.1.11.2 提供している製品・サービス・ソリューション 406
17.1.11.3 最近の動向 407
17.1.11.3.1 新製品の発売 407
17.1.11.3.2 取引実績 408
17.1.12 タカラホールディングス株式会社 409
17.1.12.1 事業概要 409
17.1.12.2 提供製品・サービス・ソリューション 410
17.1.12.3 最近の動向 410
17.1.12.3.1 取引 410
17.1.12.3.2 事業拡大 411
17.1.13 BGI GENOMICS CO., LTD. 412
17.1.13.1 事業概要 412
17.1.13.2 提供している製品・サービス・ソリューション 413
17.1.13.3 最近の動向 414
17.1.13.3.1 取引 414
17.1.14 MACROGEN, INC. 415
17.1.14.1 事業概要 415
17.1.14.2 提供製品・サービス・ソリューション 416
17.1.14.3 最近の動向 416
17.1.14.3.1 取引 416
17.1.14.3.2 事業拡大 416
17.1.15 MILTENYI BIOTEC 417
17.1.15.1 事業概要 417
17.1.15.2 提供製品・サービス・ソリューション 417
17.1.15.3 最近の動向 418
17.1.15.3.1 取引 418
17.2 その他の主要企業 419
17.2.1 BIOMARKER TECHNOLOGIES (BMKGENE) 419
17.2.2 プレシジョン・セル・システムズ社 420
17.2.3 アドメラ・ヘルス 421
17.2.4 ソニー・バイオテクノロジー社 422
17.2.5 カンタタ・バイオ 423
17.2.6 ヌクレアイ社 424
17.2.7 コンプリート・ゲノミクス社 425
17.2.8 バイオスパイダー社 426
17.2.9 シンギュラー・ゲノミクス・システムズ社 427
17.2.10 レバス・バイオシステムズ社 428
17.2.11 スペーシャル・ゲノミクス 429

18 研究方法論 430
18.1 調査データ 430
18.1.1 二次データ 431
18.1.1.1 二次資料からの主要データ 431
18.1.2 一次データ 432
18.1.2.1 一次情報源からの主要データ 432
18.1.2.2 主要な一次調査対象者 432
18.1.2.3 一次インタビューの内訳 433
18.1.2.4 主要な業界インサイト 434
18.2 市場規模の推計 435
18.2.1 2025年の世界の空間ゲノミクスおよびトランスクリプトミクス市場の推計 435
18.2.2 セグメント別市場規模の推計 438
18.3 市場成長率の予測 439
18.4 データの三角測量 440
18.5 因子分析 441
18.6 調査の前提条件 441
18.7 調査の限界およびリスク評価 442

19 付録 443
19.1 ディスカッション・ガイド 443
19.2 ナレッジストア:MarketsandMarketsのサブスクリプション・ポータル 447
19.3 カスタマイズオプション 449
19.4 関連レポート 449
19.5 著者詳細 450

ページTOPに戻る



図表リスト

FIGURE 1 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET SEGMENTATION 42.
FIGURE 2 REGIONS CONSIDERED 43.
FIGURE 3 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: YEARS CONSIDERED 44.
FIGURE 4 MARKET SCENARIO 46.
FIGURE 5 GLOBAL SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, 2024–2031 47.
FIGURE 6 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, 2023–2026 48.
FIGURE 7 DISRUPTIONS INFLUENCING GROWTH OF SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET 49.
FIGURE 8 HIGH-GROWTH SEGMENTS IN SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, 2026–2031 50.
FIGURE 9 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 51.
FIGURE 10 HIGH R&D INVESTMENTS AND INCREASED FOCUS ON DRUG DISCOVERY & DEVELOPMENT TO DRIVE MARKET 52.
FIGURE 11 PRODUCTS ACCOUNTED FOR LARGEST SHARE OF THE SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET IN NORTH AMERICA IN 2025 53.
FIGURE 12 ASIA PACIFIC IS LIKELY TO BE FASTEST-GROWING MARKET TILL 2031 54.
FIGURE 13 TRANSLATIONAL RESEARCH TO DOMINATE MARKET DURING FORECAST PERIOD 54.
FIGURE 14 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 55.
FIGURE 15 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: PORTER’S FIVE FORCES ANALYSIS 66.
FIGURE 16 VALUE CHAIN ANALYSIS 70.
FIGURE 17 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: ECOSYSTEM ANALYSIS 72.
FIGURE 18 AVERAGE SELLING PRICE OF INSTRUMENTS, BY KEY PLAYER, 2025 (USD) 74.
FIGURE 19 AVERAGE SELLING PRICE OF CONSUMABLES, BY KEY PLAYER, 2025 (USD) 75.
FIGURE 20 AVERAGE SELLING PRICE OF CONSUMABLES, BY REGION, 2025 (USD) 76.
FIGURE 21 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 79.
FIGURE 22 INVESTMENT AND FUNDING SCENARIO, 2023–2025 (USD MILLION) 80.
FIGURE 23 PATENT APPLICATIONS IN SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, JANUARY 2015-DECEMBER 2025 91.
FIGURE 24 IMPACT OF AI/GEN AI ON SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET 94.
FIGURE 25 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY OFFERING 105.
FIGURE 26 KEY BUYING CRITERIA, BY END USER (PRODUCT) 106.
FIGURE 27 KEY BUYING CRITERIA, BY END USER (SERVICES) 107.
FIGURE 28 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET SNAPSHOT 236.
FIGURE 29 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET SNAPSHOT 284.
FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS IN SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, 2021–2025 (USD MILLION) 348.
FIGURE 31 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025 349.
FIGURE 32 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 353.
FIGURE 33 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: COMPANY FOOTPRINT 354.
FIGURE 34 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 358.
FIGURE 35 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 361.
FIGURE 36 EV/EBITDA OF KEY VENDORS 361.
FIGURE 37 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: BRAND COMPARISON 362.
FIGURE 38 10X GENOMICS: COMPANY SNAPSHOT 367.
FIGURE 39 BIO-TECHNE: COMPANY SNAPSHOT 374.
FIGURE 40 BRUKER: COMPANY SNAPSHOT 380.
FIGURE 41 STANDARD BIOTOOLS INC.: COMPANY SNAPSHOT 385.
FIGURE 42 ILLUMINA, INC.: COMPANY SNAPSHOT 390.
FIGURE 43 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT 394.
FIGURE 44 DANAHER CORPORATION: COMPANY SNAPSHOT 400.
FIGURE 45 REVVITY, INC.: COMPANY SNAPSHOT 404.
FIGURE 46 TAKARA HOLDINGS INC.: COMPANY SNAPSHOT 409.
FIGURE 47 BGI GENOMICS CO., LTD.: COMPANY SNAPSHOT 413.
FIGURE 48 MACROGEN, INC.: COMPANY SNAPSHOT 415.
FIGURE 49 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: RESEARCH DESIGN 430.
FIGURE 50 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: BREAKDOWN OF PRIMARIES 433.
FIGURE 51 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: INSIGHTS FROM PRIMARIES 434.
FIGURE 52 GLOBAL SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET ESTIMATION, 2025 435.
FIGURE 53 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH) (2025) 436.
FIGURE 54 ILLUSTRATIVE EXAMPLE OF BIO-TECHNE: REVENUE ANALYSIS (2025) 436.
FIGURE 55 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 438.
FIGURE 56 SPATIAL GENOMICS AND TRANSCRIPTOMICS MARKET: CAGR PROJECTIONS 439.
FIGURE 57 SPATIAL GENOMICS AND TRANSCRIPTOMICS MARKET: DATA TRIANGULATION 440.
TABLE 1 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: INCLUSIONS AND EXCLUSIONS 43.
TABLE 2 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: IMPACT ANALYSIS.
OF MARKET DYNAMICS 56.
TABLE 3 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: PORTER’S FIVE FORCES ANALYSIS 65.
TABLE 4 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: ROLE OF PLAYERS IN ECOSYSTEM 72.
TABLE 5 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY KEY PLAYER,.
2023–2025 (USD) 73.
TABLE 6 AVERAGE SELLING PRICE TREND OF CONSUMABLES, BY KEY PLAYER,.
2023–2025 (USD) 74.
TABLE 7 AVERAGE SELLING PRICE TREND OF CONSUMABLES, BY REGION,.
2023–2025 (USD) 75.
TABLE 8 IMPORT DATA FOR HS CODE 9027-COMPLIANT PRODUCTS, BY COUNTRY,.
2021–2025 (USD THOUSAND) 76.
TABLE 9 EXPORT DATA FOR HS CODE 9027-COMPLIANT PRODUCTS, BY COUNTRY,.
2021–2025 (USD THOUSAND) 77.
TABLE 10 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2026–MARCH 2027 78.
TABLE 11 US ADJUSTED RECIPROCAL TARIFF RATES 82.
TABLE 12 CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES 83.
TABLE 13 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2015–2025 90.
TABLE 14 LIST OF KEY PATENTS IN SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, 2023-2025 92.
TABLE 15 CASE STUDIES OF AI IMPLEMENTATION IN SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET 95.
TABLE 16 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED SPATIAL GENOMICS & TRANSCRIPTOMICS TECHNOLOGIES IN SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET 97.
TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98.
TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98.
TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 99.
TABLE 20 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 99.
TABLE 21 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: INDUSTRY STANDARDS,.
BY COUNTRY 100.
TABLE 22 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY OFFERING 106.
TABLE 23 KEY BUYING CRITERIA, BY END USER (PRODUCT) 106.
TABLE 24 KEY BUYING CRITERIA, BY END USER (SERVICES) 107.
TABLE 25 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, BY OFFERING,.
2023–2031 (USD MILLION) 111.
TABLE 26 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET, BY TYPE,.
2023–2031 (USD MILLION) 111.
TABLE 27 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET, BY REGION, 2023–2031 (USD MILLION) 112.
TABLE 28 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 112.
TABLE 29 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 113.
TABLE 30 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 113.
TABLE 31 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 114.
TABLE 32 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY REGION, 2023–2031 (USD MILLION) 115.
TABLE 33 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY COUNTRY, 2023–2031 (USD MILLION) 115.
TABLE 34 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY COUNTRY, 2023–2031 (USD MILLION) 116.
TABLE 35 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY COUNTRY, 2023–2031 (USD MILLION) 116.
TABLE 36 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY COUNTRY, 2023–2031 (USD MILLION) 117.
TABLE 37 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY VOLUME, 2023–2031(UNITS) 117.
TABLE 38 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR CONSUMABLES, BY REGION, 2023–2031 (USD MILLION) 118.
TABLE 39 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR CONSUMABLES, BY COUNTRY, 2023–2031 (USD MILLION) 118.
TABLE 40 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR CONSUMABLES, BY COUNTRY, 2023–2031 (USD MILLION) 119.
TABLE 41 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR CONSUMABLES, BY COUNTRY, 2023–2031 (USD MILLION) 119.
TABLE 42 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR CONSUMABLES, BY COUNTRY, 2023–2031 (USD MILLION) 120.
TABLE 43 SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET, BY REGION,.
2023–2031 (USD MILLION) 121.
TABLE 44 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 121.
TABLE 45 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 122.
TABLE 46 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 122.
TABLE 47 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 123.
TABLE 48 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET, BY TECHNIQUE, 2023–2031 (USD MILLION) 125.
TABLE 49 SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET, BY TYPE,.
2023–2031 (USD MILLION) 126.
TABLE 50 SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET, BY REGION,.
2023–2031 (USD MILLION) 126.
TABLE 51 NORTH AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 127.
TABLE 52 EUROPE: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 127.
TABLE 53 ASIA PACIFIC: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 128.
TABLE 54 LATIN AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 128.
TABLE 55 SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2023–2031 (USD MILLION) 129.
TABLE 56 NORTH AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2023–2031 (USD MILLION) 129.
TABLE 57 EUROPE: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2023–2031 (USD MILLION) 130.
TABLE 58 ASIA PACIFIC: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2023–2031 (USD MILLION) 130.
TABLE 59 LATIN AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2023–2031 (USD MILLION) 131.
TABLE 60 SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR RNA SEQUENCING,.
BY REGION, 2023–2031 (USD MILLION) 131.
TABLE 61 NORTH AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR RNA SEQUENCING, BY COUNTRY, 2023–2031 (USD MILLION) 132.
TABLE 62 EUROPE: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR RNA SEQUENCING, BY COUNTRY, 2023–2031 (USD MILLION) 132.
TABLE 63 ASIA PACIFIC: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR RNA SEQUENCING, BY COUNTRY, 2023–2031 (USD MILLION) 133.
TABLE 64 LATIN AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR RNA SEQUENCING, BY COUNTRY, 2023–2031 (USD MILLION) 133.
TABLE 65 SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR RNA SEQUENCING, BY TYPE, 2023–2031 (USD MILLION) 133.
TABLE 66 IN SITU RNA SEQUENCING PRODUCTS MARKET, BY REGION,.
2023–2031 (USD MILLION) 134.
TABLE 67 NORTH AMERICA: IN SITU RNA SEQUENCING PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 134.
TABLE 68 EUROPE: IN SITU RNA SEQUENCING PRODUCTS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 135.
TABLE 69 ASIA PACIFIC: IN SITU RNA SEQUENCING PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 135.
TABLE 70 LATIN AMERICA: IN SITU RNA SEQUENCING PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 136.
TABLE 71 SINGLE-CELL RNA SEQUENCING PRODUCTS MARKET, BY REGION,.
2023–2031 (USD MILLION) 137.
TABLE 72 NORTH AMERICA: SINGLE-CELL RNA SEQUENCING PRODUCTS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 137.
TABLE 73 EUROPE: SINGLE-CELL RNA SEQUENCING PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 138.
TABLE 74 ASIA PACIFIC: SINGLE-CELL RNA SEQUENCING PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 138.
TABLE 75 LATIN AMERICA: SINGLE-CELL RNA SEQUENCING PRODUCTS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 139.
TABLE 76 OTHER RNA SEQUENCING PRODUCTS MARKET, BY REGION,.
2023–2031 (USD MILLION) 139.
TABLE 77 NORTH AMERICA: OTHER RNA SEQUENCING PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 140.
TABLE 78 EUROPE: OTHER RNA SEQUENCING PRODUCTS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 140.
TABLE 79 ASIA PACIFIC: OTHER RNA SEQUENCING PRODUCTS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 141.
TABLE 80 LATIN AMERICA: OTHER RNA SEQUENCING PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 141.
TABLE 81 SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR IN SITU HYBRIDIZATION,.
BY REGION, 2023–2031 (USD MILLION) 142.
TABLE 82 NORTH AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2023–2031 (USD MILLION) 142.
TABLE 83 EUROPE: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2023–2031 (USD MILLION) 143.
TABLE 84 ASIA PACIFIC: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2023–2031 (USD MILLION) 143.
TABLE 85 LATIN AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2023–2031 (USD MILLION) 144.
TABLE 86 SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR MICROSCOPY-BASED RNA IMAGING, BY REGION, 2023–2031 (USD MILLION) 145.
TABLE 87 NORTH AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR MICROSCOPY-BASED RNA IMAGING, BY COUNTRY, 2023–2031 (USD MILLION) 145.
TABLE 88 EUROPE: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR MICROSCOPY-BASED RNA IMAGING, BY COUNTRY, 2023–2031 (USD MILLION) 146.
TABLE 89 ASIA PACIFIC: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR MICROSCOPY-BASED RNA IMAGING, BY COUNTRY, 2023–2031 (USD MILLION) 146.
TABLE 90 LATIN AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR MICROSCOPY-BASED RNA IMAGING, BY COUNTRY, 2023–2031 (USD MILLION) 147.
TABLE 91 SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR IMMUNOFLUORESCENCE, BY REGION, 2023–2031 (USD MILLION) 148.
TABLE 92 NORTH AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2023–2031 (USD MILLION) 148.
TABLE 93 EUROPE: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2023–2031 (USD MILLION) 149.
TABLE 94 ASIA PACIFIC: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2023–2031 (USD MILLION) 149.
TABLE 95 LATIN AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2023–2031 (USD MILLION) 150.
TABLE 96 SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR LASER CAPTURE MICRODISSECTION, BY REGION, 2023–2031 (USD MILLION) 151.
TABLE 97 NORTH AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR LASER CAPTURE MICRODISSECTION, BY COUNTRY, 2023–2031 (USD MILLION) 151.
TABLE 98 EUROPE: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR LASER CAPTURE MICRODISSECTION, BY COUNTRY, 2023–2031 (USD MILLION) 152.
TABLE 99 ASIA PACIFIC: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR LASER CAPTURE MICRODISSECTION, BY COUNTRY, 2023–2031 (USD MILLION) 152.
TABLE 100 LATIN AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR LASER CAPTURE MICRODISSECTION, BY COUNTRY, 2023–2031 (USD MILLION) 153.
TABLE 101 SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR OTHER SPATIAL TRANSCRIPTOMICS TECHNIQUES, BY REGION, 2023–2031 (USD MILLION) 153.
TABLE 102 NORTH AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR OTHER SPATIAL TRANSCRIPTOMICS TECHNIQUES, BY COUNTRY,.
2023–2031 (USD MILLION) 154.
TABLE 103 EUROPE: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR OTHER SPATIAL TRANSCRIPTOMICS TECHNIQUES, BY COUNTRY, 2023–2031 (USD MILLION) 154.
TABLE 104 ASIA PACIFIC: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR OTHER SPATIAL TRANSCRIPTOMICS TECHNIQUES, BY COUNTRY,.
2023–2031 (USD MILLION) 155.
TABLE 105 LATIN AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR OTHER SPATIAL TRANSCRIPTOMICS TECHNIQUES, BY COUNTRY,.
2023–2031 (USD MILLION) 155.
TABLE 106 SPATIAL GENOMICS PRODUCTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 156.
TABLE 107 SPATIAL GENOMICS PRODUCTS MARKET, BY REGION, 2023–2031 (USD MILLION) 156.
TABLE 108 NORTH AMERICA: SPATIAL GENOMICS PRODUCTS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 156.
TABLE 109 EUROPE: SPATIAL GENOMICS PRODUCTS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 157.
TABLE 110 ASIA PACIFIC: SPATIAL GENOMICS PRODUCTS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 157.
TABLE 111 LATIN AMERICA: SPATIAL GENOMICS PRODUCTS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 158.
TABLE 112 SPATIAL GENOMICS PRODUCTS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2023–2031 (USD MILLION) 159.
TABLE 113 NORTH AMERICA: SPATIAL GENOMICS PRODUCTS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2023–2031 (USD MILLION) 159.
TABLE 114 EUROPE: SPATIAL GENOMICS PRODUCTS MARKET FOR IN SITU HYBRIDIZATION,.
BY COUNTRY, 2023–2031 (USD MILLION) 160.
TABLE 115 ASIA PACIFIC: SPATIAL GENOMICS PRODUCTS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2023–2031 (USD MILLION) 160.
TABLE 116 LATIN AMERICA: SPATIAL GENOMICS PRODUCTS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2023–2031 (USD MILLION) 161.
TABLE 117 SPATIAL GENOMICS PRODUCTS MARKET FOR LASER CAPTURE MICRODISSECTION, BY REGION, 2023–2031 (USD MILLION) 162.
TABLE 118 NORTH AMERICA: SPATIAL GENOMICS PRODUCTS MARKET FOR LASER CAPTURE MICRODISSECTION, BY COUNTRY, 2023–2031 (USD MILLION) 162.
TABLE 119 EUROPE: SPATIAL GENOMICS PRODUCTS MARKET FOR LASER CAPTURE MICRODISSECTION, BY COUNTRY, 2023–2031 (USD MILLION) 163.
TABLE 120 ASIA PACIFIC: SPATIAL GENOMICS PRODUCTS MARKET FOR LASER CAPTURE MICRODISSECTION, BY COUNTRY, 2023–2031 (USD MILLION) 163.
TABLE 121 LATIN AMERICA: SPATIAL GENOMICS PRODUCTS MARKET FOR LASER CAPTURE MICRODISSECTION, BY COUNTRY, 2023–2031 (USD MILLION) 164.
TABLE 122 SPATIAL GENOMICS PRODUCTS MARKET FOR GENOMIC SEQUENCING, BY TYPE, 2023–2031 (USD MILLION) 164.
TABLE 123 SPATIAL GENOMICS PRODUCTS MARKET FOR GENOMIC SEQUENCING, BY REGION, 2023–2031 (USD MILLION) 165.
TABLE 124 NORTH AMERICA: SPATIAL GENOMICS PRODUCTS MARKET FOR GENOMIC SEQUENCING, BY COUNTRY, 2023–2031 (USD MILLION) 165.
TABLE 125 EUROPE: SPATIAL GENOMICS PRODUCTS MARKET FOR GENOMIC SEQUENCING, BY COUNTRY, 2023–2031 (USD MILLION) 166.
TABLE 126 ASIA PACIFIC: SPATIAL GENOMICS PRODUCTS MARKET FOR GENOMIC SEQUENCING, BY COUNTRY, 2023–2031 (USD MILLION) 166.
TABLE 127 LATIN AMERICA: SPATIAL GENOMICS PRODUCTS MARKET FOR GENOMIC SEQUENCING, BY COUNTRY, 2023–2031 (USD MILLION) 167.
TABLE 128 MICRODISSECTION-BASED SEQUENCING PRODUCTS MARKET, BY REGION,.
2023–2031 (USD MILLION) 168.
TABLE 129 NORTH AMERICA: MICRODISSECTION-BASED SEQUENCING PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 168.
TABLE 130 EUROPE: MICRODISSECTION-BASED SEQUENCING PRODUCTS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 169.
TABLE 131 ASIA PACIFIC: MICRODISSECTION-BASED SEQUENCING PRODUCTS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 169.
TABLE 132 LATIN AMERICA: MICRODISSECTION-BASED SEQUENCING PRODUCTS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 170.
TABLE 133 CHROMATIN ACCESSIBILITY SEQUENCING PRODUCTS MARKET, BY REGION, 2023–2031 (USD MILLION) 170.
TABLE 134 NORTH AMERICA: CHROMATIN ACCESSIBILITY SEQUENCING PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 171.
TABLE 135 EUROPE: CHROMATIN ACCESSIBILITY SEQUENCING PRODUCTS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 171.
TABLE 136 ASIA PACIFIC: CHROMATIN ACCESSIBILITY SEQUENCING PRODUCTS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 172.
TABLE 137 LATIN AMERICA: CHROMATIN ACCESSIBILITY SEQUENCING PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 172.
TABLE 138 OTHER GENOMIC SEQUENCING PRODUCTS MARKET, BY REGION,.
2023–2031 (USD MILLION) 173.
TABLE 139 NORTH AMERICA: OTHER GENOMIC SEQUENCING PRODUCTS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 173.
TABLE 140 EUROPE: OTHER GENOMIC SEQUENCING PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 174.
TABLE 141 ASIA PACIFIC: OTHER GENOMIC SEQUENCING PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 174.
TABLE 142 LATIN AMERICA: OTHER GENOMIC SEQUENCING PRODUCTS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 175.
TABLE 143 SPATIAL GENOMICS PRODUCTS MARKET FOR OTHER SPATIAL GENOMICS TECHNIQUES, BY REGION, 2023–2031 (USD MILLION) 175.
TABLE 144 NORTH AMERICA: SPATIAL GENOMICS PRODUCTS MARKET FOR OTHER SPATIAL GENOMICS TECHNIQUES, BY COUNTRY, 2023–2031 (USD MILLION) 176.
TABLE 145 EUROPE: SPATIAL GENOMICS PRODUCTS MARKET FOR OTHER SPATIAL GENOMICS TECHNIQUES, BY COUNTRY, 2023–2031 (USD MILLION) 176.
TABLE 146 ASIA PACIFIC: SPATIAL GENOMICS PRODUCTS MARKET FOR OTHER SPATIAL GENOMICS TECHNIQUES, BY COUNTRY, 2023–2031 (USD MILLION) 177.
TABLE 147 LATIN AMERICA: SPATIAL GENOMICS PRODUCTS MARKET FOR OTHER SPATIAL GENOMICS TECHNIQUES, BY COUNTRY, 2023–2031 (USD MILLION) 177.
TABLE 148 SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET, BY TYPE,.
2023–2031 (USD MILLION) 179.
TABLE 149 SPATIAL GENOMICS & TRANSCRIPTOMICS SAMPLE PREPARATION SERVICES MARKET, BY REGION, 2023–2031 (USD MILLION) 180.
TABLE 150 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS SAMPLE PREPARATION SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 180.
TABLE 151 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS SAMPLE PREPARATION SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 181.
TABLE 152 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS SAMPLE PREPARATION SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 181.
TABLE 153 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS SAMPLE PREPARATION SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 182.
TABLE 154 SPATIAL GENOMICS & TRANSCRIPTOMICS SEQUENCING & ANALYTICAL SERVICES MARKET, BY REGION, 2023–2031 (USD MILLION) 182.
TABLE 155 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS SEQUENCING & ANALYTICAL SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 183.
TABLE 156 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS SEQUENCING & ANALYTICAL SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 183.
TABLE 157 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS SEQUENCING & ANALYTICAL SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 184.
TABLE 158 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS SEQUENCING & ANALYTICAL SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 184.
TABLE 159 SPATIAL GENOMICS & TRANSCRIPTOMICS DATA VISUALIZATION & ANALYSIS SERVICES MARKET, BY REGION, 2023–2031 (USD MILLION) 185.
TABLE 160 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS DATA VISUALIZATION & ANALYSIS SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 185.
TABLE 161 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS DATA VISUALIZATION & ANALYSIS SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 186.
TABLE 162 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS DATA VISUALIZATION & ANALYSIS SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 186.
TABLE 163 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS DATA VISUALIZATION & ANALYSIS SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 187.
TABLE 164 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, BY APPLICATION,.
2023–2031 (USD MILLION) 189.
TABLE 165 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET FOR TRANSLATIONAL RESEARCH, BY TYPE, 2023–2031 (USD MILLION) 190.
TABLE 166 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET FOR TRANSLATIONAL RESEARCH, BY REGION, 2023–2031 (USD MILLION) 190.
TABLE 167 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET FOR TRANSLATIONAL RESEARCH, BY COUNTRY, 2023–2031 (USD MILLION) 191.
TABLE 168 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET FOR TRANSLATIONAL RESEARCH, BY COUNTRY, 2023–2031 (USD MILLION) 191.
TABLE 169 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET FOR TRANSLATIONAL RESEARCH, BY COUNTRY, 2023–2031 (USD MILLION) 192.
TABLE 170 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET FOR TRANSLATIONAL RESEARCH, BY COUNTRY, 2023–2031 (USD MILLION) 192.
TABLE 171 TRANSLATIONAL RESEARCH MARKET FOR CANCER, BY REGION,.
2023–2031 (USD MILLION) 193.
TABLE 172 NORTH AMERICA: TRANSLATIONAL RESEARCH MARKET FOR CANCER,.
BY COUNTRY, 2023–2031 (USD MILLION) 193.
TABLE 173 EUROPE: TRANSLATIONAL RESEARCH MARKET FOR CANCER, BY COUNTRY,.
2023–2031 (USD MILLION) 194.
TABLE 174 ASIA PACIFIC: TRANSLATIONAL RESEARCH MARKET FOR CANCER, BY COUNTRY, 2023–2031 (USD MILLION) 194.
TABLE 175 LATIN AMERICA: TRANSLATIONAL RESEARCH MARKET FOR CANCER, BY COUNTRY, 2023–2031 (USD MILLION) 195.
TABLE 176 TRANSLATIONAL RESEARCH MARKET FOR IMMUNOLOGY, BY REGION,.
2023–2031 (USD MILLION) 195.
TABLE 177 NORTH AMERICA: TRANSLATIONAL RESEARCH MARKET FOR IMMUNOLOGY,.
BY COUNTRY, 2023–2031 (USD MILLION) 196.
TABLE 178 EUROPE: TRANSLATIONAL RESEARCH MARKET FOR IMMUNOLOGY, BY COUNTRY, 2023–2031 (USD MILLION) 196.
TABLE 179 ASIA PACIFIC: TRANSLATIONAL RESEARCH MARKET FOR IMMUNOLOGY,.
BY COUNTRY, 2023–2031 (USD MILLION) 197.
TABLE 180 LATIN AMERICA: TRANSLATIONAL RESEARCH MARKET FOR IMMUNOLOGY,.
BY COUNTRY, 2023–2031 (USD MILLION) 197.
TABLE 181 TRANSLATIONAL RESEARCH MARKET FOR NEUROSCIENCE, BY REGION,.
2023–2031 (USD MILLION) 198.
TABLE 182 NORTH AMERICA: TRANSLATIONAL RESEARCH MARKET FOR NEUROSCIENCE,.
BY COUNTRY, 2023–2031 (USD MILLION) 198.
TABLE 183 EUROPE: TRANSLATIONAL RESEARCH MARKET FOR NEUROSCIENCE, BY COUNTRY, 2023–2031 (USD MILLION) 199.
TABLE 184 ASIA PACIFIC: TRANSLATIONAL RESEARCH MARKET FOR NEUROSCIENCE,.
BY COUNTRY, 2023–2031 (USD MILLION) 199.
TABLE 185 LATIN AMERICA: TRANSLATIONAL RESEARCH MARKET FOR NEUROSCIENCE,.
BY COUNTRY, 2023–2031 (USD MILLION) 200.
TABLE 186 TRANSLATIONAL RESEARCH MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2031 (USD MILLION) 201.
TABLE 187 NORTH AMERICA: TRANSLATIONAL RESEARCH MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 201.
TABLE 188 EUROPE: TRANSLATIONAL RESEARCH MARKET FOR INFECTIOUS DISEASES,.
BY COUNTRY, 2023–2031 (USD MILLION) 202.
TABLE 189 ASIA PACIFIC: TRANSLATIONAL RESEARCH MARKET FOR INFECTIOUS DISEASES,.
BY COUNTRY, 2023–2031 (USD MILLION) 202.
TABLE 190 LATIN AMERICA: TRANSLATIONAL RESEARCH MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 203.
TABLE 191 TRANSLATIONAL RESEARCH MARKET FOR OTHER DISEASES, BY REGION,.
2023–2031 (USD MILLION) 203.
TABLE 192 NORTH AMERICA: TRANSLATIONAL RESEARCH MARKET FOR OTHER DISEASES,.
BY COUNTRY, 2023–2031 (USD MILLION) 204.
TABLE 193 EUROPE: TRANSLATIONAL RESEARCH MARKET FOR OTHER DISEASES,.
BY COUNTRY, 2023–2031 (USD MILLION) 204.
TABLE 194 ASIA PACIFIC: TRANSLATIONAL RESEARCH MARKET FOR OTHER DISEASES,.
BY COUNTRY, 2023–2031 (USD MILLION) 205.
TABLE 195 LATIN AMERICA: TRANSLATIONAL RESEARCH MARKET FOR OTHER DISEASES,.
BY COUNTRY, 2023–2031 (USD MILLION) 205.
TABLE 196 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2023–2031 (USD MILLION) 206.
TABLE 197 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2031 (USD MILLION) 207.
TABLE 198 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2031 (USD MILLION) 207.
TABLE 199 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2031 (USD MILLION) 208.
TABLE 200 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2031 (USD MILLION) 208.
TABLE 201 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET, BY END USER, 2023–2031 (USD MILLION) 210.
TABLE 202 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2031 (USD MILLION) 211.
TABLE 203 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY,.
2023–2031 (USD MILLION) 211.
TABLE 204 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 212.
TABLE 205 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 212.
TABLE 206 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY,.
2023–2031 (USD MILLION) 213.
TABLE 207 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR CROS & CDMOS, BY REGION, 2023–2031 (USD MILLION) 214.
TABLE 208 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2031 (USD MILLION) 214.
TABLE 209 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2031 (USD MILLION) 215.
TABLE 210 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2031 (USD MILLION) 215.
TABLE 211 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2031 (USD MILLION) 216.
TABLE 212 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION,.
2023–2031 (USD MILLION) 217.
TABLE 213 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,.
2023–2031 (USD MILLION) 217.
TABLE 214 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,.
2023–2031 (USD MILLION) 218.
TABLE 215 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,.
2023–2031 (USD MILLION) 218.
TABLE 216 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,.
2023–2031 (USD MILLION) 219.
TABLE 217 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR CLINICAL DIAGNOSTIC LABORATORIES, BY REGION, 2023–2031 (USD MILLION) 220.
TABLE 218 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR CLINICAL DIAGNOSTIC LABORATORIES, BY COUNTRY,.
2023–2031 (USD MILLION) 220.
TABLE 219 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR CLINICAL DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2031 (USD MILLION) 221.
TABLE 220 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR CLINICAL DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2031 (USD MILLION) 221.
TABLE 221 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR CLINICAL DIAGNOSTIC LABORATORIES, BY COUNTRY,.
2023–2031 (USD MILLION) 222.
TABLE 222 SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION) 224.
TABLE 223 SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2031 (USD MILLION) 225.
TABLE 224 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY,.
2023–2031 (USD MILLION) 225.
TABLE 225 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 226.
TABLE 226 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 226.
TABLE 227 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY,.
2023–2031 (USD MILLION) 227.
TABLE 228 SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION,.
2023–2031 (USD MILLION) 228.
TABLE 229 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,.
2023–2031 (USD MILLION) 228.
TABLE 230 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,.
2023–2031 (USD MILLION) 229.
TABLE 231 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,.
2023–2031 (USD MILLION) 229.
TABLE 232 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,.
2023–2031 (USD MILLION) 230.
TABLE 233 SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET FOR OTHER.
END USERS, BY REGION, 2023–2031 (USD MILLION) 231.
TABLE 234 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 231.
TABLE 235 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 232.
TABLE 236 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 232.
TABLE 237 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 233.

 

ページTOPに戻る


 

Summary

The spatial genomics & transcriptomics market is expected to grow from USD 0.67 billion in 2026 to USD 1.23 billion in 2031, at a CAGR of 12.9% during the forecast period. The market is expected to grow steadily, driven by increasing use of spatial profiling in oncology research, precision medicine, drug discovery, biomarker identification, and translational studies. Technologies such as spatial transcriptomics, in situ hybridization, sequencing-based spatial analysis, and high-plex molecular imaging enable the investigation of gene expression, cellular interactions, tissue architecture, and disease mechanisms. These tools support applications across cancer research, therapeutic target identification, treatment-response assessment, neuroscience, immunology, and developmental biology. Growing interest in single-cell analysis, multi-omics integration, and AI-enabled spatial data interpretation is further strengthening adoption across pharmaceutical, biotechnology, academic, clinical research, and CRO settings. In addition, demand for high-resolution instruments, reliable assay kits, validated probes, sequencing reagents, automated sample preparation, and bioinformatics solutions is improving workflow efficiency and data quality.

Spatial genomics segment to grow at the highest CAGR in the spatial genomics & transcriptomics products market from 2026 to 2031
By technique, the spatial genomics segment is expected to grow at the highest CAGR during the forecast period, driven by increasing demand for high-resolution analysis of gene expression within intact tissues. Growing applications in oncology, biomarker discovery, drug development, and precision medicine are increasing the need for specialized services that integrate spatial profiling with advanced data analysis. These services help researchers characterize cellular interactions, tissue architecture, and disease-associated molecular patterns, supporting deeper biological insights across pharmaceutical, biotechnology, and academic research settings.

Sequencing & analytical services segment to hold the largest share of the spatial genomics & transcriptomics services market in 2025
By type, the sequencing & analytical services segment is likely to account for the largest share of the services market in 2025, driven by the growing need to process and interpret complex spatial molecular data. These services enable researchers to analyze gene expression patterns, identify cellular interactions, and characterize tissue heterogeneity. Increasing applications in oncology, biomarker discovery, drug development, and translational research continue to support demand across pharmaceutical companies, biotechnology firms, and academic research institutes.

North America to register the second-highest CAGR in the spatial genomics & transcriptomics market between 2026 and 2031
By region, North America is expected to experience strong market growth during the forecast period, supported by substantial investments in precision medicine, advanced biomedical research infrastructure, and increasing adoption of spatial profiling technologies. Leading companies, including 10x Genomics (US), Illumina, Inc. (US), and Bruker (US), support regional growth through product innovation and platform development. Rising applications in oncology, neuroscience, biomarker discovery, and drug development, alongside pharmaceutical R&D investments and research collaborations, are expected to accelerate technology adoption across the region.

The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side – 70% and Demand Side– 30%
- By Designation: Managers – 45%, CXOs and Directors – 30%, and Executives – 25%
- By Region: North America – 40%, Europe – 25%, Asia Pacific – 25%, Latin America – 5%, and the Middle East & Africa – 5%

10x Genomics (US), Bio- Techne (US), Bruker (US), Standard BioTools Inc. (US), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), Visiopharm A/S (Denmark), Danaher Corporation (US), Velsera Inc. (US), and Revvity, Inc. (US) are some of the key companies offering spatial genomics & transcriptomics products and services.

Research Coverage
This research report categorizes the spatial genomics & transcriptomics market by offering (products and services), products market by technique (spatial transcriptomics and spatial genomics), services market by type (sample preparation services, sequencing & analytical services, and data visualization & analysis services), application (translational research and drug discovery & development), products market by end user (pharmaceutical & biotechnology companies, academic & research institutes, CROs & CDMOs, and clinical diagnostic laboratories), services market by end user (pharmaceutical & biopharmaceutical companies, academic & research institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).

The report’s scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the spatial genomics & transcriptomics market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, product & service portfolio, key strategies, new product/service launches, acquisitions, and recent developments related to the market. This report also includes a competitive analysis of emerging startups in the spatial genomics & transcriptomics ecosystem.

Key Benefits of Buying the Report
The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market’s pulse and offer information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:
- Market Dynamics: Analysis of key drivers (Increasing adoption of spatial genomics and transcriptomics in drug discovery and development, Introduction of novel spatial genomics and transcriptomics products, Increasing pharmaceutical R&D investments and public-private funding), restraints (High initial capital investments and maintenance costs, High data complexity and computational requirements), opportunities (Increasing use of spatial omics for biomarker identification, Increasing demand for precision medicines and targeted drug development), and challenges (Lack of standardization and reproducibility across spatial technologies ) influencing the spatial genomics & transcriptomics market growth
- Product Development/Innovation: Detailed insights into newly launched products and innovations in the market
- Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and products & services of leading players, such as 10x Genomics (US), Bio- Techne (US), Bruker (US), Standard BioTools Inc. (US), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), Visiopharm A/S (Denmark), and Danaher Corporation (US), among others, in the market



ページTOPに戻る


Table of Contents

1 INTRODUCTION 41
1.1 STUDY OBJECTIVES 41
1.2 MARKET DEFINITION 41
1.3 STUDY SCOPE 42
1.3.1 MARKET SEGMENTATION 42
1.3.2 REGIONAL SCOPE 43
1.3.3 INCLUSIONS & EXCLUSIONS 43
1.3.4 YEARS CONSIDERED 44
1.3.5 CURRENCY CONSIDERED 44
1.4 STAKEHOLDERS 44
1.5 SUMMARY OF CHANGES 45

2 EXECUTIVE SUMMARY 46
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 46
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 48
2.3 DISRUPTIVE TRENDS IN SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET 49
2.4 HIGH-GROWTH SEGMENTS 50
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 51

3 PREMIUM INSIGHTS 52
3.1 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET OVERVIEW 52
3.2 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, BY OFFERING 53
3.3 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 54
3.4 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET SHARE, BY APPLICATION,

2026 VS. 2031 (%) 54

4 MARKET OVERVIEW 55
4.1 INTRODUCTION 55
4.2 MARKET DYNAMICS 55
4.2.1 DRIVERS 56
4.2.1.1 Increasing adoption of spatial genomics & transcriptomics in drug discovery and development 56
4.2.1.2 Introduction of novel spatial genomics & transcriptomics products 57
4.2.1.3 Increasing pharmaceutical R&D investments and public-private funding 58
4.2.2 RESTRAINTS 59
4.2.2.1 High initial capital investments and maintenance costs 59
4.2.2.2 High data complexity and computational requirements 59
4.2.3 OPPORTUNITIES 60
4.2.3.1 Increasing use of spatial omics for biomarker identification 60
4.2.3.2 Increasing demand for precision medicines and targeted drug development 61
4.2.4 CHALLENGES 61
4.2.4.1 Lack of standardization and reproducibility across spatial technologies 61
4.3 UNMET NEEDS AND WHITE SPACES 62
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 63
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 63

5 INDUSTRY TRENDS 65
5.1 PORTER’S FIVE FORCES ANALYSIS 65
5.1.1 INTENSITY OF COMPETITIVE RIVALRY 66
5.1.2 BARGAINING POWER OF SUPPLIERS 66
5.1.3 BARGAINING POWER OF BUYERS 67
5.1.4 THREAT FROM SUBSTITUTES 67
5.1.5 THREAT FROM NEW ENTRANTS 67
5.2 MACROECONOMIC OUTLOOK 68
5.2.1 INTRODUCTION 68
5.2.2 GDP TRENDS AND FORECAST 68
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 68
5.2.4 TRENDS IN GLOBAL BIOTECH INDUSTRY 69
5.3 VALUE CHAIN ANALYSIS 69
5.4 ECOSYSTEM ANALYSIS 71
5.4.1 ROLE OF PLAYERS IN ECOSYSTEM 72
5.5 PRICING ANALYSIS 73
5.5.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2023–2025 73
5.5.1.1 Instruments 73
5.5.1.2 Consumables 74
5.5.2 AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025 75
5.6 TRADE ANALYSIS 76
5.6.1 IMPORT SCENARIO (HS CODE 9027) 76
5.6.2 EXPORT SCENARIO (HS CODE 9027) 77
5.7 KEY CONFERENCES & EVENTS, 2026–2027 78
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 78
5.9 INVESTMENT & FUNDING SCENARIO 79
5.10 CASE STUDY ANALYSIS 80
5.10.1 HIGH-RESOLUTION SPATIAL TRANSCRIPTOMICS CHARACTERIZES
THE TUMOR MICROENVIRONMENT 80
5.10.2 COSMX WHOLE-TRANSCRIPTOME IMAGING REVEALS MOLECULAR HETEROGENEITY IN KIDNEY CANCER 80
5.10.3 INTEGRATED SPATIAL GENOMICS & TRANSCRIPTOMICS REVEAL GENOME ORGANIZATION IN BREAST CANCER 81
5.11 IMPACT OF 2025 US TARIFFS—SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET 81
5.11.1 INTRODUCTION 81
5.11.2 KEY TARIFF RATES 82
5.11.3 PRICE IMPACT ANALYSIS 83
5.11.4 IMPACT ON COUNTRIES/REGIONS 84
5.11.4.1 US 84
5.11.4.2 Europe 84
5.11.4.3 Asia Pacific 85
5.11.5 IMPACT ON END-USE INDUSTRIES 85
5.11.5.1 Pharmaceutical & biotechnology companies 85
5.11.5.2 Academic & research institutes 86
5.11.5.3 CROs & CDMOs 86
5.11.5.4 Clinical diagnostic laboratories 86

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 87
6.1 TECHNOLOGY ANALYSIS 87
6.1.1 KEY TECHNOLOGIES 87
6.1.1.1 In situ sequencing 87
6.1.1.2 In situ hybridization 87
6.1.1.3 Spatial barcoding and sequencing 87
6.1.2 COMPLEMENTARY TECHNOLOGIES 88
6.1.2.1 Tissue imaging and histopathological analysis 88
6.1.2.2 Spatial heatmap 88
6.1.2.3 Differential gene expression analysis 88
6.1.3 ADJACENT TECHNOLOGIES 89
6.1.3.1 Multi-omics 89
6.1.3.2 Metabolomics 89
6.1.3.3 Single-cell analysis 89
6.2 TECHNOLOGY ROADMAP 89
6.3 PATENT ANALYSIS 90
6.3.1 METHODOLOGY 90
6.3.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE 90
6.3.3 LIST OF KEY PATENTS 92
6.4 FUTURE APPLICATIONS 92
6.5 IMPACT OF AI/GEN AI ON SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET 93
6.5.1 TOP USE CASES AND MARKET POTENTIAL 94
6.5.2 BEST PRACTICES IN AI-ENABLED SPATIAL GENOMICS & TRANSCRIPTOMICS WORKFLOWS 95
6.5.3 CASE STUDIES OF AI IMPLEMENTATION IN SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET 95
6.5.4 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 96
6.5.5 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED SPATIAL GENOMICS & TRANSCRIPTOMICS TECHNOLOGIES 96

7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 98
7.1 REGIONAL REGULATIONS AND COMPLIANCE 98
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS 98
7.1.2 INDUSTRY STANDARDS 100
7.2 SUSTAINABILITY INITIATIVES 101
7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES 102
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 102

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 105
8.1 DECISION-MAKING PROCESS 105
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 105
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 105
8.2.2 KEY BUYING CRITERIA, BY END USER (PRODUCT) 106
8.2.3 KEY BUYING CRITERIA, BY END USER (SERVICES) 107
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 108
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 109

9 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, BY OFFERING 110
9.1 INTRODUCTION 111
9.2 PRODUCTS 111
9.2.1 INSTRUMENTS & SOFTWARE 114
9.2.1.1 Instruments & software to facilitate disease research by enabling detailed spatial mapping and multi-omic analyses 114
9.2.2 CONSUMABLES 117
9.2.2.1 Better reproducible and high-quality data collection to advance spatial genomics research in oncology and precision medicine 117
9.3 SERVICES 120
9.3.1 INCREASING DEMAND FOR HIGH-QUALITY SPATIAL DATA IN PRECISION MEDICINE TO AUGMENT MARKET GROWTH 120

10 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET,
BY TECHNIQUE 124
10.1 INTRODUCTION 125
10.2 SPATIAL TRANSCRIPTOMICS 125
10.2.1 IMMUNOHISTOCHEMISTRY 128
10.2.1.1 Increasing applications in biomarker discovery and cellular interactions within tissue architecture to drive segment 128
10.2.2 RNA SEQUENCING 131
10.2.2.1 In situ RNA sequencing 134
10.2.2.1.1 Integration of ISS with bioinformatics toolkits for data analysis to facilitate interpretation of complex datasets 134
10.2.2.2 Single-cell RNA sequencing 136
10.2.2.2.1 Increasing commercial availability of scRNA-seq platforms and advancements in bioinformatics tools to drive segment 136
10.2.2.3 Other RNA sequencing 139
10.2.3 IN SITU HYBRIDIZATION 141
10.2.3.1 High-throughput and 3D spatial gene expression analysis in cancer research and developmental biology to drive segment 141
10.2.4 MICROSCOPY-BASED RNA IMAGING 144
10.2.4.1 Better insights into molecular communication within tissue architecture to augment segment growth 144
10.2.5 IMMUNOFLUORESCENCE 147
10.2.5.1 Advanced profiling of immune-tumor microenvironments for cancer diagnosis and prognosis to propel segment growth 147
10.2.6 LASER CAPTURE MICRODISSECTION 150
10.2.6.1 Analysis of gene expression data from defined cellular populations to facilitate spatial mapping within tissue sections 150
10.2.7 OTHER SPATIAL TRANSCRIPTOMICS TECHNIQUES 153
10.3 SPATIAL GENOMICS 155
10.3.1 IN SITU HYBRIDIZATION 158
10.3.1.1 Demand for high-specificity detection platforms to fuel market growth 158
10.3.2 LASER CAPTURE MICRODISSECTION 161
10.3.2.1 Detailed insights into cellular mechanisms and molecular profiles within heterogeneous tissue samples to drive segment 161
10.3.3 GENOMIC SEQUENCING 164
10.3.3.1 Microdissection-based sequencing 167
10.3.3.1.1 Increased demand for precision medicines to boost segment growth 167
10.3.3.2 Chromatin accessibility sequencing 170
10.3.3.2.1 Need for insights into gene regulation and epigenetic modifications to aid segment growth 170
10.3.3.3 Other genomic sequencing 172
10.3.4 OTHER SPATIAL GENOMICS TECHNIQUES 175

11 SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET, BY TYPE 178
11.1 INTRODUCTION 179
11.2 SAMPLE PREPARATION SERVICES 179
11.2.1 NEED FOR ACCURATE SPATIAL ANALYSIS OF GENE EXPRESSION WITHIN TISSUE SAMPLES TO SPUR MARKET GROWTH 179
11.3 SEQUENCING & ANALYTICAL SERVICES 182
11.3.1 SEQUENCING & ANALYTICAL SERVICES TO UTILIZE ADVANCED TECHNOLOGIES FOR SEQUENCING AND BIOINFORMATICS ANALYSIS 182
11.4 DATA VISUALIZATION & ANALYSIS SERVICES 184
11.4.1 INCREASED DEMAND FOR ADVANCED TOOLS FOR COMPLEX SPATIAL GENOMICS DATA INTERPRETATION TO SUPPORT MARKET GROWTH 184

12 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, BY APPLICATION 188
12.1 INTRODUCTION 189
12.2 TRANSLATIONAL RESEARCH 189
12.2.1 CANCER 192
12.2.1.1 Spatial genomics and transcriptomics to map precise locations of DNA and RNA within tumor tissues in cancer research 192
12.2.2 IMMUNOLOGY 195
12.2.2.1 Need for better understanding of immune cell interactions and tissue-specific immune responses to propel segment growth 195
12.2.3 NEUROSCIENCE 197
12.2.3.1 Increased focus on mapping cellular diversity for analyzing brain function and dysfunction to aid market growth 197
12.2.4 INFECTIOUS DISEASES 200
12.2.4.1 Need for enhanced understanding of pathogen-host interactions at tissue level to drive adoption 200
12.2.5 OTHER DISEASES 203
12.3 DRUG DISCOVERY & DEVELOPMENT 206
12.3.1 RISING USE OF RNA-SEQ IN DISEASE MANAGEMENT AND DRUG DISCOVERY TO DRIVE MARKET 206

13 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET
BY END USER 209
13.1 INTRODUCTION 210
13.2 ACADEMIC & RESEARCH INSTITUTES 210
13.2.1 FOCUS ON FOUNDATIONAL DISCOVERIES AND CELLULAR INSIGHTS ABOUT COMPLEX BIOLOGICAL SYSTEMS TO AID MARKET GROWTH 210
13.3 CROS & CDMOS 213
13.3.1 GROWING DEMAND FOR PRECISE SPATIAL MOLECULAR INSIGHTS TO PROPEL MARKET GROWTH 213
13.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 216
13.4.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO TRANSFORM DISEASE RESEARCH AND STREAMLINE DRUG TARGET VALIDATION 216
13.5 CLINICAL DIAGNOSTIC LABORATORIES 219
13.5.1 IMPROVED DIAGNOSTIC ACCURACY IN PATHOGEN DETECTION AND GENOMIC ANALYSIS TO AID MARKET GROWTH 219

14 SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET, BY END USER 223
14.1 INTRODUCTION 224
14.2 ACADEMIC & RESEARCH INSTITUTES 224
14.2.1 NEED FOR TOOLS FOR MAPPING CELLULAR ENVIRONMENTS AND STUDYING DISEASE MECHANISMS TO PROPEL MARKET GROWTH 224
14.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 227
14.3.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO OPTIMIZE BIOMARKER DEVELOPMENT AND IMPROVE CLINICAL TRIAL DESIGN 227
14.4 OTHER END USERS 230

15 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, BY REGION 234
15.1 INTRODUCTION 235
15.2 NORTH AMERICA 236
15.2.1 US 241
15.2.1.1 US to dominate North American spatial genomics & transcriptomics market during forecast period 241
15.2.2 CANADA 246
15.2.2.1 Favorable government initiatives and high incidence of infectious diseases to support market growth 246
15.3 EUROPE 251
15.3.1 GERMANY 256
15.3.1.1 Advanced genomics research and presence of several key companies to spur market growth 256
15.3.2 UK 261
15.3.2.1 Increasing government funding and rising demand for new diagnostic biomarkers to aid market growth 261
15.3.3 FRANCE 265
15.3.3.1 Increasing investments in life science R&D and rising number of biotech companies to propel market growth 265
15.3.4 ITALY 270
15.3.4.1 Increasing focus on disease research and expanding diagnostic capabilities to augment market growth 270
15.3.5 SPAIN 274
15.3.5.1 Focus on advanced cancer research and increased need for personalized medicines to propel market growth 274
15.3.6 REST OF EUROPE 279
15.4 ASIA PACIFIC 284
15.4.1 CHINA 290
15.4.1.1 Advancing domestic spatial technologies and AI-enabled data analysis are strengthening spatial biology research 290
15.4.2 JAPAN 294
15.4.2.1 Strategic acquisitions and integrated spatial workflows are accelerating technology adoption 294
15.4.3 INDIA 299
15.4.3.1 Expanding genomics research and precision oncology are creating opportunities for spatial analysis technologies 299
15.4.4 SOUTH KOREA 303
15.4.4.1 Biotechnology investment and research access programs are supporting spatial transcriptomics adoption 303
15.4.5 AUSTRALIA 308
15.4.5.1 Research infrastructure and industry partnerships are expanding access to spatial omics technologies 308
15.4.6 REST OF ASIA PACIFIC 312
15.5 LATIN AMERICA 317
15.5.1 BRAZIL 322
15.5.1.1 National genomics initiatives and precision public health are creating pathways for spatial transcriptomics adoption 322
15.5.2 MEXICO 327
15.5.2.1 Strengthening genomic research infrastructure and computational expertise is supporting spatial biology opportunities 327
15.5.3 REST OF LATIN AMERICA 331
15.6 MIDDLE EAST 336
15.7 AFRICA 341

16 COMPETITIVE LANDSCAPE 346
16.1 INTRODUCTION 346
16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, JANUARY 2023–SEPTEMBER 2026 346
16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS,
JANUARY 2023–SEPTEMBER 2026 346
16.3 REVENUE ANALYSIS, 2021–2025 348
16.4 MARKET SHARE ANALYSIS, 2025 349
16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 352
16.5.1 STARS 352
16.5.2 EMERGING LEADERS 352
16.5.3 PERVASIVE PLAYERS 352
16.5.4 PARTICIPANTS 352
16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 354
16.5.5.1 Company footprint 354
16.5.5.2 Region footprint 354
16.5.5.3 Offering footprint 355
16.5.5.4 Technique footprint 356
16.5.5.5 Application footprint 356
16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 357
16.6.1 PROGRESSIVE COMPANIES 357
16.6.2 RESPONSIVE COMPANIES 357
16.6.3 DYNAMIC COMPANIES 357
16.6.4 STARTING BLOCKS 357
16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 359
16.6.5.1 Detailed list of key startup/SME players 359
16.6.5.2 Competitive benchmarking of startups/SMEs 360
16.7 COMPANY VALUATION AND FINANCIAL METRICS 361
16.7.1 COMPANY VALUATION 361
16.7.2 COMPANY VALUATION 361
16.8 BRAND COMPARISON 362
16.9 COMPETITIVE SCENARIO 363
16.9.1 PRODUCT LAUNCHES 363
16.9.2 DEALS 364
16.9.3 EXPANSIONS 365

17 COMPANY PROFILES 366
17.1 KEY PLAYERS 366
17.1.1 10X GENOMICS 366
17.1.1.1 Business overview 366
17.1.1.2 Products/Services/Solutions offered 367
17.1.1.3 Recent developments 369
17.1.1.3.1 Product/Service launches 369
17.1.1.3.2 Deals 370
17.1.1.3.3 Expansions 371
17.1.1.4 MnM view 372
17.1.1.4.1 Key strengths 372
17.1.1.4.2 Strategic choices 372
17.1.1.4.3 Weaknesses and competitive threats 372
17.1.2 BIO-TECHNE 373
17.1.2.1 Business overview 373
17.1.2.2 Products/Services/Solutions offered 374
17.1.2.3 Recent developments 376
17.1.2.3.1 Product/Service launches 376
17.1.2.3.2 Deals 377
17.1.2.4 MnM view 377
17.1.2.4.1 Key strengths 377
17.1.2.4.2 Strategic choices 377
17.1.2.4.3 Weaknesses and competitive threats 378
17.1.3 BRUKER 379
17.1.3.1 Business overview 379
17.1.3.2 Products/Services/Solutions offered 380
17.1.3.3 Recent developments 381
17.1.3.3.1 Deals 381
17.1.3.4 MnM view 382
17.1.3.4.1 Key strengths 382
17.1.3.4.2 Strategic choices 382
17.1.3.4.3 Weaknesses and competitive threats 383
17.1.4 STANDARD BIOTOOLS INC. 384
17.1.4.1 Business overview 384
17.1.4.2 Products/Services/Solutions offered 385
17.1.4.3 Recent developments 387
17.1.4.3.1 Product launches 387
17.1.4.3.2 Deals 388
17.1.4.4 MnM view 388
17.1.4.4.1 Key strengths 388
17.1.4.4.2 Strategic choices 388
17.1.4.4.3 Weaknesses and competitive threats 388
17.1.5 ILLUMINA, INC. 389
17.1.5.1 Business overview 389
17.1.5.2 Products/Services/Solutions offered 390
17.1.5.3 Recent developments 391
17.1.5.3.1 Product launches 391
17.1.5.3.2 Deals 392
17.1.5.4 MnM view 392
17.1.5.4.1 Key strengths 392
17.1.5.4.2 Strategic choices 392
17.1.5.4.3 Weaknesses and competitive threats 392
17.1.6 BIO-RAD LABORATORIES, INC. 393
17.1.6.1 Business overview 393
17.1.6.2 Products/Services/Solutions offered 394
17.1.6.3 Recent developments 395
17.1.6.3.1 Product launches 395
17.1.6.3.2 Deals 395
17.1.6.4 MnM view 395
17.1.6.4.1 Key strengths 395
17.1.6.4.2 Strategic choices 395
17.1.6.4.3 Weaknesses and competitive threats 396
17.1.7 VISIOPHARM A/S 397
17.1.7.1 Business overview 397
17.1.7.2 Products/Services/Solutions offered 397
17.1.7.3 Recent developments 398
17.1.7.3.1 Product launches 398
17.1.8 DANAHER CORPORATION 399
17.1.8.1 Business overview 399
17.1.8.2 Products/Services/Solutions offered 400
17.1.8.3 Recent developments 401
17.1.8.3.1 Deals 401
17.1.9 VELSERA INC. 402
17.1.9.1 Business overview 402
17.1.9.2 Products/Services/Solutions offered 402
17.1.10 REVVITY, INC. 403
17.1.10.1 Business overview 403
17.1.10.2 Products/Services/Solutions offered 404
17.1.10.3 Recent developments 405
17.1.10.3.1 Deals 405
17.1.11 VIZGEN, INC. 406
17.1.11.1 Business overview 406
17.1.11.2 Products/Services/Solutions offered 406
17.1.11.3 Recent developments 407
17.1.11.3.1 Product launches 407
17.1.11.3.2 Deals 408
17.1.12 TAKARA HOLDINGS INC. 409
17.1.12.1 Business overview 409
17.1.12.2 Products/Services/Solutions offered 410
17.1.12.3 Recent developments 410
17.1.12.3.1 Deals 410
17.1.12.3.2 Expansions 411
17.1.13 BGI GENOMICS CO., LTD. 412
17.1.13.1 Business overview 412
17.1.13.2 Products/Services/Solutions offered 413
17.1.13.3 Recent developments 414
17.1.13.3.1 Deals 414
17.1.14 MACROGEN, INC. 415
17.1.14.1 Business overview 415
17.1.14.2 Products/Services/Solutions offered 416
17.1.14.3 Recent developments 416
17.1.14.3.1 Deals 416
17.1.14.3.2 Expansions 416
17.1.15 MILTENYI BIOTEC 417
17.1.15.1 Business overview 417
17.1.15.2 Products/Services/Solutions offered 417
17.1.15.3 Recent developments 418
17.1.15.3.1 Deals 418
17.2 OTHER PLAYERS 419
17.2.1 BIOMARKER TECHNOLOGIES (BMKGENE) 419
17.2.2 PRECISION CELL SYSTEMS, INC. 420
17.2.3 ADMERA HEALTH 421
17.2.4 SONY BIOTECHNOLOGY INC. 422
17.2.5 CANTATA BIO 423
17.2.6 NUCLEAI, INC. 424
17.2.7 COMPLETE GENOMICS INCORPORATED 425
17.2.8 BIOSPYDER, INC. 426
17.2.9 SINGULAR GENOMICS SYSTEMS, INC. 427
17.2.10 REBUS BIOSYSTEMS, INC. 428
17.2.11 SPATIAL GENOMICS 429

18 RESEARCH METHODOLOGY 430
18.1 RESEARCH DATA 430
18.1.1 SECONDARY DATA 431
18.1.1.1 Key data from secondary sources 431
18.1.2 PRIMARY DATA 432
18.1.2.1 Key data from primary sources 432
18.1.2.2 Key primary participants 432
18.1.2.3 Breakdown of primary interviews 433
18.1.2.4 Key industry insights 434
18.2 MARKET SIZE ESTIMATION 435
18.2.1 GLOBAL SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET ESTIMATION, 2025 435
18.2.2 SEGMENTAL MARKET SIZE ESTIMATION 438
18.3 MARKET GROWTH RATE PROJECTIONS 439
18.4 DATA TRIANGULATION 440
18.5 FACTOR ANALYSIS 441
18.6 RESEARCH ASSUMPTIONS 441
18.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT 442

19 APPENDIX 443
19.1 DISCUSSION GUIDE 443
19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 447
19.3 CUSTOMIZATION OPTIONS 449
19.4 RELATED REPORTS 449
19.5 AUTHOR DETAILS 450

ページTOPに戻る



List of Tables/Graphs

FIGURE 1 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET SEGMENTATION 42.
FIGURE 2 REGIONS CONSIDERED 43.
FIGURE 3 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: YEARS CONSIDERED 44.
FIGURE 4 MARKET SCENARIO 46.
FIGURE 5 GLOBAL SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, 2024–2031 47.
FIGURE 6 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, 2023–2026 48.
FIGURE 7 DISRUPTIONS INFLUENCING GROWTH OF SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET 49.
FIGURE 8 HIGH-GROWTH SEGMENTS IN SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, 2026–2031 50.
FIGURE 9 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 51.
FIGURE 10 HIGH R&D INVESTMENTS AND INCREASED FOCUS ON DRUG DISCOVERY & DEVELOPMENT TO DRIVE MARKET 52.
FIGURE 11 PRODUCTS ACCOUNTED FOR LARGEST SHARE OF THE SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET IN NORTH AMERICA IN 2025 53.
FIGURE 12 ASIA PACIFIC IS LIKELY TO BE FASTEST-GROWING MARKET TILL 2031 54.
FIGURE 13 TRANSLATIONAL RESEARCH TO DOMINATE MARKET DURING FORECAST PERIOD 54.
FIGURE 14 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 55.
FIGURE 15 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: PORTER’S FIVE FORCES ANALYSIS 66.
FIGURE 16 VALUE CHAIN ANALYSIS 70.
FIGURE 17 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: ECOSYSTEM ANALYSIS 72.
FIGURE 18 AVERAGE SELLING PRICE OF INSTRUMENTS, BY KEY PLAYER, 2025 (USD) 74.
FIGURE 19 AVERAGE SELLING PRICE OF CONSUMABLES, BY KEY PLAYER, 2025 (USD) 75.
FIGURE 20 AVERAGE SELLING PRICE OF CONSUMABLES, BY REGION, 2025 (USD) 76.
FIGURE 21 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 79.
FIGURE 22 INVESTMENT AND FUNDING SCENARIO, 2023–2025 (USD MILLION) 80.
FIGURE 23 PATENT APPLICATIONS IN SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, JANUARY 2015-DECEMBER 2025 91.
FIGURE 24 IMPACT OF AI/GEN AI ON SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET 94.
FIGURE 25 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY OFFERING 105.
FIGURE 26 KEY BUYING CRITERIA, BY END USER (PRODUCT) 106.
FIGURE 27 KEY BUYING CRITERIA, BY END USER (SERVICES) 107.
FIGURE 28 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET SNAPSHOT 236.
FIGURE 29 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET SNAPSHOT 284.
FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS IN SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, 2021–2025 (USD MILLION) 348.
FIGURE 31 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025 349.
FIGURE 32 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 353.
FIGURE 33 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: COMPANY FOOTPRINT 354.
FIGURE 34 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 358.
FIGURE 35 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 361.
FIGURE 36 EV/EBITDA OF KEY VENDORS 361.
FIGURE 37 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: BRAND COMPARISON 362.
FIGURE 38 10X GENOMICS: COMPANY SNAPSHOT 367.
FIGURE 39 BIO-TECHNE: COMPANY SNAPSHOT 374.
FIGURE 40 BRUKER: COMPANY SNAPSHOT 380.
FIGURE 41 STANDARD BIOTOOLS INC.: COMPANY SNAPSHOT 385.
FIGURE 42 ILLUMINA, INC.: COMPANY SNAPSHOT 390.
FIGURE 43 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT 394.
FIGURE 44 DANAHER CORPORATION: COMPANY SNAPSHOT 400.
FIGURE 45 REVVITY, INC.: COMPANY SNAPSHOT 404.
FIGURE 46 TAKARA HOLDINGS INC.: COMPANY SNAPSHOT 409.
FIGURE 47 BGI GENOMICS CO., LTD.: COMPANY SNAPSHOT 413.
FIGURE 48 MACROGEN, INC.: COMPANY SNAPSHOT 415.
FIGURE 49 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: RESEARCH DESIGN 430.
FIGURE 50 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: BREAKDOWN OF PRIMARIES 433.
FIGURE 51 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: INSIGHTS FROM PRIMARIES 434.
FIGURE 52 GLOBAL SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET ESTIMATION, 2025 435.
FIGURE 53 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH) (2025) 436.
FIGURE 54 ILLUSTRATIVE EXAMPLE OF BIO-TECHNE: REVENUE ANALYSIS (2025) 436.
FIGURE 55 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 438.
FIGURE 56 SPATIAL GENOMICS AND TRANSCRIPTOMICS MARKET: CAGR PROJECTIONS 439.
FIGURE 57 SPATIAL GENOMICS AND TRANSCRIPTOMICS MARKET: DATA TRIANGULATION 440.
TABLE 1 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: INCLUSIONS AND EXCLUSIONS 43.
TABLE 2 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: IMPACT ANALYSIS.
OF MARKET DYNAMICS 56.
TABLE 3 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: PORTER’S FIVE FORCES ANALYSIS 65.
TABLE 4 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: ROLE OF PLAYERS IN ECOSYSTEM 72.
TABLE 5 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY KEY PLAYER,.
2023–2025 (USD) 73.
TABLE 6 AVERAGE SELLING PRICE TREND OF CONSUMABLES, BY KEY PLAYER,.
2023–2025 (USD) 74.
TABLE 7 AVERAGE SELLING PRICE TREND OF CONSUMABLES, BY REGION,.
2023–2025 (USD) 75.
TABLE 8 IMPORT DATA FOR HS CODE 9027-COMPLIANT PRODUCTS, BY COUNTRY,.
2021–2025 (USD THOUSAND) 76.
TABLE 9 EXPORT DATA FOR HS CODE 9027-COMPLIANT PRODUCTS, BY COUNTRY,.
2021–2025 (USD THOUSAND) 77.
TABLE 10 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2026–MARCH 2027 78.
TABLE 11 US ADJUSTED RECIPROCAL TARIFF RATES 82.
TABLE 12 CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES 83.
TABLE 13 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2015–2025 90.
TABLE 14 LIST OF KEY PATENTS IN SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, 2023-2025 92.
TABLE 15 CASE STUDIES OF AI IMPLEMENTATION IN SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET 95.
TABLE 16 CLIENTS’ READINESS TO ADOPT AI-INTEGRATED SPATIAL GENOMICS & TRANSCRIPTOMICS TECHNOLOGIES IN SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET 97.
TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98.
TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98.
TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 99.
TABLE 20 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 99.
TABLE 21 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET: INDUSTRY STANDARDS,.
BY COUNTRY 100.
TABLE 22 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY OFFERING 106.
TABLE 23 KEY BUYING CRITERIA, BY END USER (PRODUCT) 106.
TABLE 24 KEY BUYING CRITERIA, BY END USER (SERVICES) 107.
TABLE 25 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, BY OFFERING,.
2023–2031 (USD MILLION) 111.
TABLE 26 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET, BY TYPE,.
2023–2031 (USD MILLION) 111.
TABLE 27 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET, BY REGION, 2023–2031 (USD MILLION) 112.
TABLE 28 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 112.
TABLE 29 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 113.
TABLE 30 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 113.
TABLE 31 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 114.
TABLE 32 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY REGION, 2023–2031 (USD MILLION) 115.
TABLE 33 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY COUNTRY, 2023–2031 (USD MILLION) 115.
TABLE 34 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY COUNTRY, 2023–2031 (USD MILLION) 116.
TABLE 35 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY COUNTRY, 2023–2031 (USD MILLION) 116.
TABLE 36 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY COUNTRY, 2023–2031 (USD MILLION) 117.
TABLE 37 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY VOLUME, 2023–2031(UNITS) 117.
TABLE 38 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR CONSUMABLES, BY REGION, 2023–2031 (USD MILLION) 118.
TABLE 39 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR CONSUMABLES, BY COUNTRY, 2023–2031 (USD MILLION) 118.
TABLE 40 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR CONSUMABLES, BY COUNTRY, 2023–2031 (USD MILLION) 119.
TABLE 41 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR CONSUMABLES, BY COUNTRY, 2023–2031 (USD MILLION) 119.
TABLE 42 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR CONSUMABLES, BY COUNTRY, 2023–2031 (USD MILLION) 120.
TABLE 43 SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET, BY REGION,.
2023–2031 (USD MILLION) 121.
TABLE 44 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 121.
TABLE 45 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 122.
TABLE 46 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 122.
TABLE 47 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 123.
TABLE 48 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET, BY TECHNIQUE, 2023–2031 (USD MILLION) 125.
TABLE 49 SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET, BY TYPE,.
2023–2031 (USD MILLION) 126.
TABLE 50 SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET, BY REGION,.
2023–2031 (USD MILLION) 126.
TABLE 51 NORTH AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 127.
TABLE 52 EUROPE: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 127.
TABLE 53 ASIA PACIFIC: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 128.
TABLE 54 LATIN AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 128.
TABLE 55 SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2023–2031 (USD MILLION) 129.
TABLE 56 NORTH AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2023–2031 (USD MILLION) 129.
TABLE 57 EUROPE: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2023–2031 (USD MILLION) 130.
TABLE 58 ASIA PACIFIC: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2023–2031 (USD MILLION) 130.
TABLE 59 LATIN AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2023–2031 (USD MILLION) 131.
TABLE 60 SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR RNA SEQUENCING,.
BY REGION, 2023–2031 (USD MILLION) 131.
TABLE 61 NORTH AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR RNA SEQUENCING, BY COUNTRY, 2023–2031 (USD MILLION) 132.
TABLE 62 EUROPE: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR RNA SEQUENCING, BY COUNTRY, 2023–2031 (USD MILLION) 132.
TABLE 63 ASIA PACIFIC: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR RNA SEQUENCING, BY COUNTRY, 2023–2031 (USD MILLION) 133.
TABLE 64 LATIN AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR RNA SEQUENCING, BY COUNTRY, 2023–2031 (USD MILLION) 133.
TABLE 65 SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR RNA SEQUENCING, BY TYPE, 2023–2031 (USD MILLION) 133.
TABLE 66 IN SITU RNA SEQUENCING PRODUCTS MARKET, BY REGION,.
2023–2031 (USD MILLION) 134.
TABLE 67 NORTH AMERICA: IN SITU RNA SEQUENCING PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 134.
TABLE 68 EUROPE: IN SITU RNA SEQUENCING PRODUCTS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 135.
TABLE 69 ASIA PACIFIC: IN SITU RNA SEQUENCING PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 135.
TABLE 70 LATIN AMERICA: IN SITU RNA SEQUENCING PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 136.
TABLE 71 SINGLE-CELL RNA SEQUENCING PRODUCTS MARKET, BY REGION,.
2023–2031 (USD MILLION) 137.
TABLE 72 NORTH AMERICA: SINGLE-CELL RNA SEQUENCING PRODUCTS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 137.
TABLE 73 EUROPE: SINGLE-CELL RNA SEQUENCING PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 138.
TABLE 74 ASIA PACIFIC: SINGLE-CELL RNA SEQUENCING PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 138.
TABLE 75 LATIN AMERICA: SINGLE-CELL RNA SEQUENCING PRODUCTS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 139.
TABLE 76 OTHER RNA SEQUENCING PRODUCTS MARKET, BY REGION,.
2023–2031 (USD MILLION) 139.
TABLE 77 NORTH AMERICA: OTHER RNA SEQUENCING PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 140.
TABLE 78 EUROPE: OTHER RNA SEQUENCING PRODUCTS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 140.
TABLE 79 ASIA PACIFIC: OTHER RNA SEQUENCING PRODUCTS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 141.
TABLE 80 LATIN AMERICA: OTHER RNA SEQUENCING PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 141.
TABLE 81 SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR IN SITU HYBRIDIZATION,.
BY REGION, 2023–2031 (USD MILLION) 142.
TABLE 82 NORTH AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2023–2031 (USD MILLION) 142.
TABLE 83 EUROPE: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2023–2031 (USD MILLION) 143.
TABLE 84 ASIA PACIFIC: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2023–2031 (USD MILLION) 143.
TABLE 85 LATIN AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2023–2031 (USD MILLION) 144.
TABLE 86 SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR MICROSCOPY-BASED RNA IMAGING, BY REGION, 2023–2031 (USD MILLION) 145.
TABLE 87 NORTH AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR MICROSCOPY-BASED RNA IMAGING, BY COUNTRY, 2023–2031 (USD MILLION) 145.
TABLE 88 EUROPE: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR MICROSCOPY-BASED RNA IMAGING, BY COUNTRY, 2023–2031 (USD MILLION) 146.
TABLE 89 ASIA PACIFIC: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR MICROSCOPY-BASED RNA IMAGING, BY COUNTRY, 2023–2031 (USD MILLION) 146.
TABLE 90 LATIN AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR MICROSCOPY-BASED RNA IMAGING, BY COUNTRY, 2023–2031 (USD MILLION) 147.
TABLE 91 SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR IMMUNOFLUORESCENCE, BY REGION, 2023–2031 (USD MILLION) 148.
TABLE 92 NORTH AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2023–2031 (USD MILLION) 148.
TABLE 93 EUROPE: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2023–2031 (USD MILLION) 149.
TABLE 94 ASIA PACIFIC: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2023–2031 (USD MILLION) 149.
TABLE 95 LATIN AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2023–2031 (USD MILLION) 150.
TABLE 96 SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR LASER CAPTURE MICRODISSECTION, BY REGION, 2023–2031 (USD MILLION) 151.
TABLE 97 NORTH AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR LASER CAPTURE MICRODISSECTION, BY COUNTRY, 2023–2031 (USD MILLION) 151.
TABLE 98 EUROPE: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR LASER CAPTURE MICRODISSECTION, BY COUNTRY, 2023–2031 (USD MILLION) 152.
TABLE 99 ASIA PACIFIC: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR LASER CAPTURE MICRODISSECTION, BY COUNTRY, 2023–2031 (USD MILLION) 152.
TABLE 100 LATIN AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR LASER CAPTURE MICRODISSECTION, BY COUNTRY, 2023–2031 (USD MILLION) 153.
TABLE 101 SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR OTHER SPATIAL TRANSCRIPTOMICS TECHNIQUES, BY REGION, 2023–2031 (USD MILLION) 153.
TABLE 102 NORTH AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR OTHER SPATIAL TRANSCRIPTOMICS TECHNIQUES, BY COUNTRY,.
2023–2031 (USD MILLION) 154.
TABLE 103 EUROPE: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR OTHER SPATIAL TRANSCRIPTOMICS TECHNIQUES, BY COUNTRY, 2023–2031 (USD MILLION) 154.
TABLE 104 ASIA PACIFIC: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR OTHER SPATIAL TRANSCRIPTOMICS TECHNIQUES, BY COUNTRY,.
2023–2031 (USD MILLION) 155.
TABLE 105 LATIN AMERICA: SPATIAL TRANSCRIPTOMICS PRODUCTS MARKET FOR OTHER SPATIAL TRANSCRIPTOMICS TECHNIQUES, BY COUNTRY,.
2023–2031 (USD MILLION) 155.
TABLE 106 SPATIAL GENOMICS PRODUCTS MARKET, BY TYPE, 2023–2031 (USD MILLION) 156.
TABLE 107 SPATIAL GENOMICS PRODUCTS MARKET, BY REGION, 2023–2031 (USD MILLION) 156.
TABLE 108 NORTH AMERICA: SPATIAL GENOMICS PRODUCTS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 156.
TABLE 109 EUROPE: SPATIAL GENOMICS PRODUCTS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 157.
TABLE 110 ASIA PACIFIC: SPATIAL GENOMICS PRODUCTS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 157.
TABLE 111 LATIN AMERICA: SPATIAL GENOMICS PRODUCTS MARKET, BY COUNTRY,.
2023–2031 (USD MILLION) 158.
TABLE 112 SPATIAL GENOMICS PRODUCTS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2023–2031 (USD MILLION) 159.
TABLE 113 NORTH AMERICA: SPATIAL GENOMICS PRODUCTS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2023–2031 (USD MILLION) 159.
TABLE 114 EUROPE: SPATIAL GENOMICS PRODUCTS MARKET FOR IN SITU HYBRIDIZATION,.
BY COUNTRY, 2023–2031 (USD MILLION) 160.
TABLE 115 ASIA PACIFIC: SPATIAL GENOMICS PRODUCTS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2023–2031 (USD MILLION) 160.
TABLE 116 LATIN AMERICA: SPATIAL GENOMICS PRODUCTS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2023–2031 (USD MILLION) 161.
TABLE 117 SPATIAL GENOMICS PRODUCTS MARKET FOR LASER CAPTURE MICRODISSECTION, BY REGION, 2023–2031 (USD MILLION) 162.
TABLE 118 NORTH AMERICA: SPATIAL GENOMICS PRODUCTS MARKET FOR LASER CAPTURE MICRODISSECTION, BY COUNTRY, 2023–2031 (USD MILLION) 162.
TABLE 119 EUROPE: SPATIAL GENOMICS PRODUCTS MARKET FOR LASER CAPTURE MICRODISSECTION, BY COUNTRY, 2023–2031 (USD MILLION) 163.
TABLE 120 ASIA PACIFIC: SPATIAL GENOMICS PRODUCTS MARKET FOR LASER CAPTURE MICRODISSECTION, BY COUNTRY, 2023–2031 (USD MILLION) 163.
TABLE 121 LATIN AMERICA: SPATIAL GENOMICS PRODUCTS MARKET FOR LASER CAPTURE MICRODISSECTION, BY COUNTRY, 2023–2031 (USD MILLION) 164.
TABLE 122 SPATIAL GENOMICS PRODUCTS MARKET FOR GENOMIC SEQUENCING, BY TYPE, 2023–2031 (USD MILLION) 164.
TABLE 123 SPATIAL GENOMICS PRODUCTS MARKET FOR GENOMIC SEQUENCING, BY REGION, 2023–2031 (USD MILLION) 165.
TABLE 124 NORTH AMERICA: SPATIAL GENOMICS PRODUCTS MARKET FOR GENOMIC SEQUENCING, BY COUNTRY, 2023–2031 (USD MILLION) 165.
TABLE 125 EUROPE: SPATIAL GENOMICS PRODUCTS MARKET FOR GENOMIC SEQUENCING, BY COUNTRY, 2023–2031 (USD MILLION) 166.
TABLE 126 ASIA PACIFIC: SPATIAL GENOMICS PRODUCTS MARKET FOR GENOMIC SEQUENCING, BY COUNTRY, 2023–2031 (USD MILLION) 166.
TABLE 127 LATIN AMERICA: SPATIAL GENOMICS PRODUCTS MARKET FOR GENOMIC SEQUENCING, BY COUNTRY, 2023–2031 (USD MILLION) 167.
TABLE 128 MICRODISSECTION-BASED SEQUENCING PRODUCTS MARKET, BY REGION,.
2023–2031 (USD MILLION) 168.
TABLE 129 NORTH AMERICA: MICRODISSECTION-BASED SEQUENCING PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 168.
TABLE 130 EUROPE: MICRODISSECTION-BASED SEQUENCING PRODUCTS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 169.
TABLE 131 ASIA PACIFIC: MICRODISSECTION-BASED SEQUENCING PRODUCTS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 169.
TABLE 132 LATIN AMERICA: MICRODISSECTION-BASED SEQUENCING PRODUCTS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 170.
TABLE 133 CHROMATIN ACCESSIBILITY SEQUENCING PRODUCTS MARKET, BY REGION, 2023–2031 (USD MILLION) 170.
TABLE 134 NORTH AMERICA: CHROMATIN ACCESSIBILITY SEQUENCING PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 171.
TABLE 135 EUROPE: CHROMATIN ACCESSIBILITY SEQUENCING PRODUCTS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 171.
TABLE 136 ASIA PACIFIC: CHROMATIN ACCESSIBILITY SEQUENCING PRODUCTS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 172.
TABLE 137 LATIN AMERICA: CHROMATIN ACCESSIBILITY SEQUENCING PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 172.
TABLE 138 OTHER GENOMIC SEQUENCING PRODUCTS MARKET, BY REGION,.
2023–2031 (USD MILLION) 173.
TABLE 139 NORTH AMERICA: OTHER GENOMIC SEQUENCING PRODUCTS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 173.
TABLE 140 EUROPE: OTHER GENOMIC SEQUENCING PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 174.
TABLE 141 ASIA PACIFIC: OTHER GENOMIC SEQUENCING PRODUCTS MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 174.
TABLE 142 LATIN AMERICA: OTHER GENOMIC SEQUENCING PRODUCTS MARKET,.
BY COUNTRY, 2023–2031 (USD MILLION) 175.
TABLE 143 SPATIAL GENOMICS PRODUCTS MARKET FOR OTHER SPATIAL GENOMICS TECHNIQUES, BY REGION, 2023–2031 (USD MILLION) 175.
TABLE 144 NORTH AMERICA: SPATIAL GENOMICS PRODUCTS MARKET FOR OTHER SPATIAL GENOMICS TECHNIQUES, BY COUNTRY, 2023–2031 (USD MILLION) 176.
TABLE 145 EUROPE: SPATIAL GENOMICS PRODUCTS MARKET FOR OTHER SPATIAL GENOMICS TECHNIQUES, BY COUNTRY, 2023–2031 (USD MILLION) 176.
TABLE 146 ASIA PACIFIC: SPATIAL GENOMICS PRODUCTS MARKET FOR OTHER SPATIAL GENOMICS TECHNIQUES, BY COUNTRY, 2023–2031 (USD MILLION) 177.
TABLE 147 LATIN AMERICA: SPATIAL GENOMICS PRODUCTS MARKET FOR OTHER SPATIAL GENOMICS TECHNIQUES, BY COUNTRY, 2023–2031 (USD MILLION) 177.
TABLE 148 SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET, BY TYPE,.
2023–2031 (USD MILLION) 179.
TABLE 149 SPATIAL GENOMICS & TRANSCRIPTOMICS SAMPLE PREPARATION SERVICES MARKET, BY REGION, 2023–2031 (USD MILLION) 180.
TABLE 150 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS SAMPLE PREPARATION SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 180.
TABLE 151 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS SAMPLE PREPARATION SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 181.
TABLE 152 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS SAMPLE PREPARATION SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 181.
TABLE 153 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS SAMPLE PREPARATION SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 182.
TABLE 154 SPATIAL GENOMICS & TRANSCRIPTOMICS SEQUENCING & ANALYTICAL SERVICES MARKET, BY REGION, 2023–2031 (USD MILLION) 182.
TABLE 155 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS SEQUENCING & ANALYTICAL SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 183.
TABLE 156 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS SEQUENCING & ANALYTICAL SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 183.
TABLE 157 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS SEQUENCING & ANALYTICAL SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 184.
TABLE 158 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS SEQUENCING & ANALYTICAL SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 184.
TABLE 159 SPATIAL GENOMICS & TRANSCRIPTOMICS DATA VISUALIZATION & ANALYSIS SERVICES MARKET, BY REGION, 2023–2031 (USD MILLION) 185.
TABLE 160 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS DATA VISUALIZATION & ANALYSIS SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 185.
TABLE 161 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS DATA VISUALIZATION & ANALYSIS SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 186.
TABLE 162 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS DATA VISUALIZATION & ANALYSIS SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 186.
TABLE 163 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS DATA VISUALIZATION & ANALYSIS SERVICES MARKET, BY COUNTRY, 2023–2031 (USD MILLION) 187.
TABLE 164 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, BY APPLICATION,.
2023–2031 (USD MILLION) 189.
TABLE 165 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET FOR TRANSLATIONAL RESEARCH, BY TYPE, 2023–2031 (USD MILLION) 190.
TABLE 166 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET FOR TRANSLATIONAL RESEARCH, BY REGION, 2023–2031 (USD MILLION) 190.
TABLE 167 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET FOR TRANSLATIONAL RESEARCH, BY COUNTRY, 2023–2031 (USD MILLION) 191.
TABLE 168 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET FOR TRANSLATIONAL RESEARCH, BY COUNTRY, 2023–2031 (USD MILLION) 191.
TABLE 169 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET FOR TRANSLATIONAL RESEARCH, BY COUNTRY, 2023–2031 (USD MILLION) 192.
TABLE 170 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET FOR TRANSLATIONAL RESEARCH, BY COUNTRY, 2023–2031 (USD MILLION) 192.
TABLE 171 TRANSLATIONAL RESEARCH MARKET FOR CANCER, BY REGION,.
2023–2031 (USD MILLION) 193.
TABLE 172 NORTH AMERICA: TRANSLATIONAL RESEARCH MARKET FOR CANCER,.
BY COUNTRY, 2023–2031 (USD MILLION) 193.
TABLE 173 EUROPE: TRANSLATIONAL RESEARCH MARKET FOR CANCER, BY COUNTRY,.
2023–2031 (USD MILLION) 194.
TABLE 174 ASIA PACIFIC: TRANSLATIONAL RESEARCH MARKET FOR CANCER, BY COUNTRY, 2023–2031 (USD MILLION) 194.
TABLE 175 LATIN AMERICA: TRANSLATIONAL RESEARCH MARKET FOR CANCER, BY COUNTRY, 2023–2031 (USD MILLION) 195.
TABLE 176 TRANSLATIONAL RESEARCH MARKET FOR IMMUNOLOGY, BY REGION,.
2023–2031 (USD MILLION) 195.
TABLE 177 NORTH AMERICA: TRANSLATIONAL RESEARCH MARKET FOR IMMUNOLOGY,.
BY COUNTRY, 2023–2031 (USD MILLION) 196.
TABLE 178 EUROPE: TRANSLATIONAL RESEARCH MARKET FOR IMMUNOLOGY, BY COUNTRY, 2023–2031 (USD MILLION) 196.
TABLE 179 ASIA PACIFIC: TRANSLATIONAL RESEARCH MARKET FOR IMMUNOLOGY,.
BY COUNTRY, 2023–2031 (USD MILLION) 197.
TABLE 180 LATIN AMERICA: TRANSLATIONAL RESEARCH MARKET FOR IMMUNOLOGY,.
BY COUNTRY, 2023–2031 (USD MILLION) 197.
TABLE 181 TRANSLATIONAL RESEARCH MARKET FOR NEUROSCIENCE, BY REGION,.
2023–2031 (USD MILLION) 198.
TABLE 182 NORTH AMERICA: TRANSLATIONAL RESEARCH MARKET FOR NEUROSCIENCE,.
BY COUNTRY, 2023–2031 (USD MILLION) 198.
TABLE 183 EUROPE: TRANSLATIONAL RESEARCH MARKET FOR NEUROSCIENCE, BY COUNTRY, 2023–2031 (USD MILLION) 199.
TABLE 184 ASIA PACIFIC: TRANSLATIONAL RESEARCH MARKET FOR NEUROSCIENCE,.
BY COUNTRY, 2023–2031 (USD MILLION) 199.
TABLE 185 LATIN AMERICA: TRANSLATIONAL RESEARCH MARKET FOR NEUROSCIENCE,.
BY COUNTRY, 2023–2031 (USD MILLION) 200.
TABLE 186 TRANSLATIONAL RESEARCH MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2031 (USD MILLION) 201.
TABLE 187 NORTH AMERICA: TRANSLATIONAL RESEARCH MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 201.
TABLE 188 EUROPE: TRANSLATIONAL RESEARCH MARKET FOR INFECTIOUS DISEASES,.
BY COUNTRY, 2023–2031 (USD MILLION) 202.
TABLE 189 ASIA PACIFIC: TRANSLATIONAL RESEARCH MARKET FOR INFECTIOUS DISEASES,.
BY COUNTRY, 2023–2031 (USD MILLION) 202.
TABLE 190 LATIN AMERICA: TRANSLATIONAL RESEARCH MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2031 (USD MILLION) 203.
TABLE 191 TRANSLATIONAL RESEARCH MARKET FOR OTHER DISEASES, BY REGION,.
2023–2031 (USD MILLION) 203.
TABLE 192 NORTH AMERICA: TRANSLATIONAL RESEARCH MARKET FOR OTHER DISEASES,.
BY COUNTRY, 2023–2031 (USD MILLION) 204.
TABLE 193 EUROPE: TRANSLATIONAL RESEARCH MARKET FOR OTHER DISEASES,.
BY COUNTRY, 2023–2031 (USD MILLION) 204.
TABLE 194 ASIA PACIFIC: TRANSLATIONAL RESEARCH MARKET FOR OTHER DISEASES,.
BY COUNTRY, 2023–2031 (USD MILLION) 205.
TABLE 195 LATIN AMERICA: TRANSLATIONAL RESEARCH MARKET FOR OTHER DISEASES,.
BY COUNTRY, 2023–2031 (USD MILLION) 205.
TABLE 196 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2023–2031 (USD MILLION) 206.
TABLE 197 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2031 (USD MILLION) 207.
TABLE 198 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2031 (USD MILLION) 207.
TABLE 199 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2031 (USD MILLION) 208.
TABLE 200 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2031 (USD MILLION) 208.
TABLE 201 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET, BY END USER, 2023–2031 (USD MILLION) 210.
TABLE 202 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2031 (USD MILLION) 211.
TABLE 203 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY,.
2023–2031 (USD MILLION) 211.
TABLE 204 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 212.
TABLE 205 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 212.
TABLE 206 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY,.
2023–2031 (USD MILLION) 213.
TABLE 207 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR CROS & CDMOS, BY REGION, 2023–2031 (USD MILLION) 214.
TABLE 208 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2031 (USD MILLION) 214.
TABLE 209 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2031 (USD MILLION) 215.
TABLE 210 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2031 (USD MILLION) 215.
TABLE 211 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2031 (USD MILLION) 216.
TABLE 212 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION,.
2023–2031 (USD MILLION) 217.
TABLE 213 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,.
2023–2031 (USD MILLION) 217.
TABLE 214 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,.
2023–2031 (USD MILLION) 218.
TABLE 215 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,.
2023–2031 (USD MILLION) 218.
TABLE 216 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,.
2023–2031 (USD MILLION) 219.
TABLE 217 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR CLINICAL DIAGNOSTIC LABORATORIES, BY REGION, 2023–2031 (USD MILLION) 220.
TABLE 218 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR CLINICAL DIAGNOSTIC LABORATORIES, BY COUNTRY,.
2023–2031 (USD MILLION) 220.
TABLE 219 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR CLINICAL DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2031 (USD MILLION) 221.
TABLE 220 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR CLINICAL DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2031 (USD MILLION) 221.
TABLE 221 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET FOR CLINICAL DIAGNOSTIC LABORATORIES, BY COUNTRY,.
2023–2031 (USD MILLION) 222.
TABLE 222 SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET, BY END USER, 2023–2031 (USD MILLION) 224.
TABLE 223 SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2031 (USD MILLION) 225.
TABLE 224 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY,.
2023–2031 (USD MILLION) 225.
TABLE 225 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 226.
TABLE 226 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2031 (USD MILLION) 226.
TABLE 227 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY,.
2023–2031 (USD MILLION) 227.
TABLE 228 SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION,.
2023–2031 (USD MILLION) 228.
TABLE 229 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,.
2023–2031 (USD MILLION) 228.
TABLE 230 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,.
2023–2031 (USD MILLION) 229.
TABLE 231 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,.
2023–2031 (USD MILLION) 229.
TABLE 232 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,.
2023–2031 (USD MILLION) 230.
TABLE 233 SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET FOR OTHER.
END USERS, BY REGION, 2023–2031 (USD MILLION) 231.
TABLE 234 NORTH AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 231.
TABLE 235 EUROPE: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 232.
TABLE 236 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 232.
TABLE 237 LATIN AMERICA: SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2031 (USD MILLION) 233.

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(バイオ薬物)の最新刊レポート

MarketsandMarkets社の Biotechnology分野 での最新刊レポート

本レポートと同じKEY WORD(genomics)の最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ(MarketsandMarkets)は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。


詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

 

2026/11/19 10:27

160.48 円

176.53 円

213.76 円

ページTOPに戻る